<article article-type="research-article" dtd-version="1.4" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Mol Gastroenterol Hepatol</journal-id><journal-id journal-id-type="iso-abbrev">Cell Mol Gastroenterol Hepatol</journal-id><journal-id journal-id-type="pmc-domain-id">3079</journal-id><journal-id journal-id-type="pmc-domain">cmgh</journal-id><journal-title-group><journal-title>Cellular and Molecular Gastroenterology and Hepatology</journal-title></journal-title-group><issn pub-type="epub">2352-345X</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12860731</article-id><article-id pub-id-type="pmcid-ver">PMC12860731.1</article-id><article-id pub-id-type="pmcaid">12860731</article-id><article-id pub-id-type="pmcaiid">12860731</article-id><article-id pub-id-type="pmid">41389877</article-id><article-id pub-id-type="doi">10.1016/j.jcmgh.2025.101707</article-id><article-id pub-id-type="pii">S2352-345X(25)00249-8</article-id><article-id pub-id-type="publisher-id">101707</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Metabolic Signatures of <italic toggle="yes">Acinetobacter baumannii</italic> and <italic toggle="yes">Klebsiella pneumoniae</italic> Infections in Acute-on-chronic Liver Failure</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Cadoli</surname><given-names initials="C">Camilla</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Arif</surname><given-names initials="S">Sania</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Ballhorn</surname><given-names initials="W">Wibke</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Brieger</surname><given-names initials="A">Angela</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Brol</surname><given-names initials="MJ">Maximilian Joseph</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Castelli</surname><given-names initials="F">Florence</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Erasmus</surname><given-names initials="HP">Hans-Peter</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Fischer</surname><given-names initials="J">Julia</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Gurke</surname><given-names initials="R">Robert</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Hahnefeld</surname><given-names initials="L">Lisa</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author" id="au11"><name name-style="western"><surname>Junot</surname><given-names initials="C">Christophe</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author" id="au12"><name name-style="western"><surname>Kraus</surname><given-names initials="N">Nico</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author" id="au13"><name name-style="western"><surname>Ortiz</surname><given-names initials="C">Cristina</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author" id="au14"><name name-style="western"><surname>Schierwagen</surname><given-names initials="R">Robert</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author" id="au15"><name name-style="western"><surname>Torres</surname><given-names initials="SG">Sara Garcia</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" id="au16"><name name-style="western"><surname>Uschner</surname><given-names initials="FE">Frank Erhard</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author" id="au17"><name name-style="western"><surname>Müller</surname><given-names initials="V">Volker</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author" id="au18"><name name-style="western"><surname>Trebicka</surname><given-names initials="J">Jonel</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author" id="au19"><name name-style="western"><surname>Welsch</surname><given-names initials="C">Christoph</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author" id="au20"><name name-style="western"><surname>Kempf</surname><given-names initials="VAJ">Volkhard A.J.</given-names></name><email>volkhard.kempf@ukffm.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">∗</xref></contrib><aff id="aff1"><label>1</label>Institute of Medical Microbiology and Infection Control, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany</aff><aff id="aff2"><label>2</label>Department of Medicine B (Gastroenterology, Hepatology, Endocrinology, Clinical Infectiology), University Hospital Muenster, Muenster, Germany</aff><aff id="aff3"><label>3</label>Medical Clinic 1, Biomedical Research Laboratory, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany</aff><aff id="aff4"><label>4</label>Département Médicaments et Technologies pour la Santé (MTS), Université Paris-Saclay, CEA, INRAE, Gif-sur-Yvette, France</aff><aff id="aff5"><label>5</label>MetaboHUB, Gif-sur-Yvette, France</aff><aff id="aff6"><label>6</label>Molecular Hepatology and Inflammation Research, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany</aff><aff id="aff7"><label>7</label>Faculty of Medicine, Institute of Clinical Pharmacology, Frankfurt am Main, Germany</aff><aff id="aff8"><label>8</label>Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany</aff><aff id="aff9"><label>9</label>Fraunhofer Cluster of Excellence Immune-mediated Diseases CIMD, Frankfurt am Main, Germany</aff><aff id="aff10"><label>10</label>Institute of Molecular Biosciences, Goethe University Frankfurt, Frankfurt am Main, Germany</aff><aff id="aff11"><label>11</label>European Foundation for the Study of Chronic Liver Failure - EF CLIF, Barcelona, Spain</aff></contrib-group><author-notes><corresp id="cor1"><label>∗</label><bold>Correspondence</bold> Address correspondence to: Volkhard A.J. Kempf, MD, Institute for Medical Microbiology and Infection Control, University Hospital, Goethe University, Paul-Ehrlich-Str. 40, Frankfurt am Main D-60596, Germany. <email>volkhard.kempf@ukffm.de</email></corresp></author-notes><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>12</day><month>12</month><year>2025</year></pub-date><volume>20</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">506597</issue-id><elocation-id>101707</elocation-id><history><date date-type="received"><day>22</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>3</day><month>12</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>12</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-02 08:25:13.163"><day>02</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref content-type="ccbylicense" specific-use="textmining" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="main.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><abstract id="abs0010"><sec><title>Background &amp; Aims</title><p>Acute-on-chronic liver failure (ACLF) is a life-threatening syndrome of acute hepatic decompensation (AD) that leads to multiorgan failure and high mortality. Bacterial infections are often implicated in ACLF pathogenesis; however, their underlying molecular mechanisms remain poorly understood. This study employed a combined in vitro-ex vivo metabolomics approach to investigate infection-associated metabolic alterations relevant to ACLF.</p></sec><sec><title>Methods</title><p>Gut (Caco-2) cells were infected with <italic toggle="yes">Acinetobacter baumannii</italic> and <italic toggle="yes">Klebsiella pneumoniae</italic> strains. Metabolite profiling was conducted on cell culture supernatants, and selected metabolites were tested for hepatotoxicity in vitro using liver (HepG2) cells. Metabolomic analysis of sera from 2 independent patient cohorts (AD and ACLF) was conducted to validate in vitro findings and to assess their clinical relevance.</p></sec><sec><title>Results</title><p>Distinct metabolic signatures were identified in <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> (19 metabolites) and <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic> (15 metabolites)-infected Caco-2 cells. Four key metabolites from each bacterial species were prioritized for further experiments: α-ketoglutarate, indoleacetic acid, p-coumaric acid, uridine (<italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic>), desthiobiotin, N8-acetylspermidine, N-acetylglutamine, and β-pinene (<italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic>). Hepatotoxicity was demonstrated in liver (HepG2) cells exposed to Caco-2 infected cell-derived supernatants, infection-associated metabolites, and metabolite mixtures (in all conditions, <italic toggle="yes">P</italic> &lt; .0001). Increased levels of α-ketoglutarate (<italic toggle="yes">P</italic> = .0002), N-acetylglutamine (<italic toggle="yes">P</italic> = .0153), indoleacetic acid (<italic toggle="yes">P</italic> &lt; .05), and N8-acetylspermidine (<italic toggle="yes">P</italic> &lt; .01) have been confirmed in the sera of patients with AD and ACLF.</p></sec><sec><title>Conclusions</title><p>Our findings suggest that metabolites associated with bacterial infections and hepatotoxic potential are significantly elevated in patients with AD and ACLF. These compounds may contribute to disease-related metabolic disturbances, representing promising candidates as early diagnostic biomarkers and targeted therapeutic strategies for ACLF.</p></sec></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><fig id="undfig1" orientation="portrait" position="anchor"><graphic orientation="portrait" position="float" xlink:href="ga1.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Infection-associated Metabolites</kwd><kwd>Liver Disease</kwd><kwd>Metabolomic Profiling</kwd><kwd>Potential Biomarkers</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta><def-list><title>Abbreviations used in this paper</title><def-item><term id="kwrd0035">AB</term><def><p>A baumannii</p></def></def-item><def-item><term id="kwrd0045">ACLF</term><def><p>acute-on-chronic liver failure</p></def></def-item><def-item><term id="kwrd0055">AD</term><def><p>acute decompensation</p></def></def-item><def-item><term id="kwrd0065">ALT</term><def><p>alanine aminotransaminase</p></def></def-item><def-item><term id="kwrd0075">AMPA</term><def><p>2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl) propanoic acid</p></def></def-item><def-item><term id="kwrd0085">ANOVA</term><def><p>analysis of variance</p></def></def-item><def-item><term id="kwrd0095">AST</term><def><p>aspartate aminotransaminase</p></def></def-item><def-item><term id="kwrd0105">BSA</term><def><p>bovine serum albumin</p></def></def-item><def-item><term id="kwrd0115">CBA</term><def><p>Columbia blood agar</p></def></def-item><def-item><term id="kwrd0125">CFU</term><def><p>colony forming unit</p></def></def-item><def-item><term id="kwrd0135">CRP</term><def><p>C-reactive protein</p></def></def-item><def-item><term id="kwrd0145">CV</term><def><p>cubital vein</p></def></def-item><def-item><term id="kwrd0155">DAPI</term><def><p>4′,6-diamidino-2-phenylindole</p></def></def-item><def-item><term id="kwrd0165">DMEM</term><def><p>Dulbecco’s Modified Eagle Medium</p></def></def-item><def-item><term id="kwrd0175">DMSO</term><def><p>dimethyl sulfoxide</p></def></def-item><def-item><term id="kwrd0185">EDTA</term><def><p>ethylene diamine tetra-acetic acid</p></def></def-item><def-item><term id="kwrd0195">ESI</term><def><p>electrospray</p></def></def-item><def-item><term id="kwrd0205">ESS</term><def><p>external standards solution</p></def></def-item><def-item><term id="kwrd0215">FCS</term><def><p>fetal calf serum</p></def></def-item><def-item><term id="kwrd0225">HCD</term><def><p>higher-energy C-trap dissociation</p></def></def-item><def-item><term id="kwrd0235">HIF-1α</term><def><p>hypoxia-inducible factor 1-alpha</p></def></def-item><def-item><term id="kwrd0245">HILIC</term><def><p>hydrophilic interaction chromatography</p></def></def-item><def-item><term id="kwrd0255">IgG</term><def><p>immunoglobulin G</p></def></def-item><def-item><term id="kwrd0265">INR</term><def><p>International Normalized Ratio</p></def></def-item><def-item><term id="kwrd0275">KP</term><def><p>K pneumoniae</p></def></def-item><def-item><term id="kwrd0285">LC-HRMS</term><def><p>liquid chromatography coupled to high resolution mass spectrometry</p></def></def-item><def-item><term id="kwrd0295">LV</term><def><p>hepatic vein</p></def></def-item><def-item><term id="kwrd0305">MCPA</term><def><p>2-methyl-4-chlorophenoxyacetic acid</p></def></def-item><def-item><term id="kwrd0315">MDR</term><def><p>multidrug-resistant</p></def></def-item><def-item><term id="kwrd0325">MELD</term><def><p>Model of End-stage Liver Disease</p></def></def-item><def-item><term id="kwrd0335">MOI</term><def><p>multiplicity of infection</p></def></def-item><def-item><term id="kwrd0345">MS/MS</term><def><p>tandem mass spectrometry</p></def></def-item><def-item><term id="kwrd0355">NADH</term><def><p>nicotinamide adenine dinucleotide phosphate, reduced form</p></def></def-item><def-item><term id="kwrd0365">NIST</term><def><p>National Institute of Standards and Technology</p></def></def-item><def-item><term id="kwrd0375">OD</term><def><p>optical density</p></def></def-item><def-item><term id="kwrd0385">p</term><def><p>passage number</p></def></def-item><def-item><term id="kwrd0395">PBS</term><def><p>phosphate buffered saline</p></def></def-item><def-item><term id="kwrd0405">PV</term><def><p>portal vein</p></def></def-item><def-item><term id="kwrd0415">QC</term><def><p>quality control</p></def></def-item><def-item><term id="kwrd0425">ROS</term><def><p>reactive oxygen species</p></def></def-item><def-item><term id="kwrd0435">RT</term><def><p>room temperature</p></def></def-item><def-item><term id="kwrd0445">SCFAs</term><def><p>short-chain fatty acid</p></def></def-item><def-item><term id="kwrd0455">SD</term><def><p>standard deviation</p></def></def-item><def-item><term id="kwrd0465">SRM</term><def><p>Standard Reference Material</p></def></def-item><def-item><term id="kwrd0475">TIPS</term><def><p>transjugular intrahepatic portosystemic shunt</p></def></def-item><def-item><term id="kwrd0485">TRITC</term><def><p>tetramethylrhodamine</p></def></def-item><def-item><term id="kwrd0495">UHPLC</term><def><p>ultra-high-performance liquid chromatography</p></def></def-item><def-item><term id="kwrd0505">WBC</term><def><p>white blood cell</p></def></def-item><def-item><term id="kwrd0515">WHO</term><def><p>World Health Organization</p></def></def-item><def-item><term id="kwrd0525">XTT</term><def><p>sodium 3'-(1-(phenylaminocarbonyl)-3,4-tetrazolium)-bis(4-methoxy-6-nitro) benzene sulfonic acid hydrate</p></def></def-item></def-list></front><body><p id="p0010">
<boxed-text id="dtbox1" orientation="portrait" position="float"><caption><title>Summary</title></caption><p id="p0015">Bacterial infections contribute to acute-on-chronic liver failure onset. In vitro models reveal that metabolites from <italic toggle="yes">Acinetobacter baumannii</italic> and <italic toggle="yes">Klebsiella pneumoniae</italic> infection induce specific hepatotoxic compounds, which were subsequently detected in sera of patients with acute hepatic decompensation and sera from patients with acute-on-chronic liver failure.</p></boxed-text>
<boxed-text id="dtbox2" orientation="portrait" position="float"><caption><title>What You Need to Know</title></caption><sec id="dtbox2sec1"><title>Background</title><p id="p0025">Bacterial infections often trigger acute-on-chronic liver failure, yet mechanisms remain unclear. This study uses metabolomics and in vitro–ex vivo models to identify hepatotoxic infection-associated metabolites.</p></sec><sec id="dtbox2sec2"><title>Impact</title><p id="p0030">Distinct metabolites from <italic toggle="yes">Acinetobacter baumannii</italic> and <italic toggle="yes">Klebsiella pneumoniae</italic> infections induce hepatocyte injury and are elevated in sera from patients with acute decompensation and acute-on-chronic liver failure, representing candidate biomarkers and targeted therapeutic strategies.</p></sec><sec id="dtbox2sec3"><title>Future Directions</title><p id="p0035">These findings pave the way for the development of biomarkers, targeted therapies, and modulation of the gut-liver axis to prevent infection-associated liver injury in patients with acute decompensation and acute-on-chronic liver failure.</p></sec></boxed-text>
</p><p id="p0040">Acute-on-chronic liver failure (ACLF) is a clinical syndrome defined by acute hepatic decompensation (AD) in individuals with advanced chronic liver disease, leading to multi-organ failure and high short-term mortality, often within weeks.<xref ref-type="bibr" rid="bib1"><sup>1</sup></xref> Infections are and alcohol abuse are common triggers, with bacterial infections accounting for 35% of cases globally.<xref ref-type="bibr" rid="bib2"><sup>2</sup></xref> Bacteria and bacterial metabolite translocation into the liver activate inflammatory cascades, worsen portal hypertension, and accelerate liver injury.<xref ref-type="bibr" rid="bib3"><sup>3</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib4"><sup>4</sup></xref> Despite its clinical significance, ACLF pathogenesis remains insufficiently characterized. Emerging evidence highlights the gut-liver axis as a key driver, where gut dysbiosis, an imbalance in microbial composition, and compromised barrier integrity, enables microbial products to enter portal circulation, fueling hepatic inflammation and organ dysfunction.<xref ref-type="bibr" rid="bib3">3</xref>, <xref ref-type="bibr" rid="bib4">4</xref>, <xref ref-type="bibr" rid="bib5">5</xref> Frequent hospitalization and the use of broad-spectrum antibiotics in patients with ACLF further disrupt microbial homeostasis, promoting pathological overgrowth of antibiotic-resistant bacteria in the gut.<xref ref-type="bibr" rid="bib6"><sup>6</sup></xref>
<italic toggle="yes">Klebsiella pneumoniae</italic> and <italic toggle="yes">Acinetobacter baumannii</italic> have been prioritized by the World Health Organization (WHO) as urgent health threats due to their carbapenem resistance and increasing clinical prevalence.<xref ref-type="bibr" rid="bib7"><sup>7</sup></xref>
<italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic>, a dominant gut colonizer, is linked to spontaneous bacterial peritonitis and bloodstream infections, common ACLF precipitants.<xref ref-type="bibr" rid="bib8"><sup>8</sup></xref>
<italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic> causes severe nosocomial infections in immunocompromised hosts, including those with liver disease.<xref ref-type="bibr" rid="bib7"><sup>7</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib9"><sup>9</sup></xref> In ACLF, colonization by these pathogens can rapidly escalate to invasive infection and organ failure.<xref ref-type="bibr" rid="bib7"><sup>7</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib9"><sup>9</sup></xref> Subsequent metabolic dysregulation affects multiple organ systems, involving alterations in amino acids, lipids, bile acids, and microbial-derived compounds, with bacterial infections driving shifts in energy metabolism and disease severity.<xref ref-type="bibr" rid="bib10"><sup>10</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib11"><sup>11</sup></xref> Metabolites, byproducts of microbial and host metabolism, can both sustain homeostasis and disrupt metabolic balance.<xref ref-type="bibr" rid="bib10"><sup>10</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib12"><sup>12</sup></xref> To reflect microbial dynamics in patients with ACLF, this study investigates the metabolic impact of <italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic> and <italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic> on the disease using laboratory reference strains,<xref ref-type="bibr" rid="bib13"><sup>13</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib14"><sup>14</sup></xref> patient-derived multidrug-resistant (carbapenem-resistant), and highly virulent clinical strains.<xref ref-type="bibr" rid="bib15"><sup>15</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib16"><sup>16</sup></xref> This study leverages metabolomics, a comprehensive analysis of metabolites within biological systems, to infection models and patient datasets. This strategy aims to identify profile metabolic alterations and infection-associated metabolites in ACLF, providing insights into the interplay between bacterial infections and host metabolic imbalance, paving the way for innovative therapeutic strategies.</p><sec id="sec1"><title>Results</title><sec id="sec1.1"><title>Infections of Caco-2 cells With <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> or <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic></title><p id="p0045">ACLF is often worsened by bacterial infections with Gram-negative bacteria due to compromised intestinal barrier integrity, allowing microbial translocation and further liver damage.<xref ref-type="bibr" rid="bib3"><sup>3</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib17"><sup>17</sup></xref> To emulate this in vivo response, we employed gut cells (Caco-2) with various <italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic> and <italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic> strains (<xref ref-type="table" rid="tbl1">Table 1</xref>; see <xref ref-type="sec" rid="sec3">Materials and Methods</xref>). A 6-hour infection window was selected to preserve cell integrity, avoid bacterial overgrowth, and ensure consistency across all bacterial strains. Infections were conducted at MOI 100 (<italic toggle="yes">A baumannii</italic>) and MOI 1 (<italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic>) and analyzed via double immunofluorescence (<xref ref-type="fig" rid="fig1">Figure 1</xref><italic toggle="yes">A</italic>). Microscopy showed no major differences in cellular phenotypes across infections with reference, multidrug-resistant (MDR), or highly virulent strains, supporting the physiological relevance of the infection conditions.<table-wrap id="tbl1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Bacterial Strains Used in This Study</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Strains</th><th colspan="1" rowspan="1">Source of isolation</th><th colspan="1" rowspan="1">Year of isolation</th><th colspan="1" rowspan="1">Origin</th><th colspan="1" rowspan="1">Resistance genes</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><italic toggle="yes">Acinetobacter baumannii</italic></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> AB 1: wild-type <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic><xref ref-type="bibr" rid="bib13"><sup>13</sup></xref></td><td colspan="1" rowspan="1">Urine</td><td align="char" colspan="1" rowspan="1">1948</td><td colspan="1" rowspan="1">ATCC 19606<sup>T</sup></td><td colspan="1" rowspan="1"><italic toggle="yes">sul2</italic></td></tr><tr><td colspan="1" rowspan="1"> AB 2: MDR</td><td colspan="1" rowspan="1">Nose swab</td><td align="char" colspan="1" rowspan="1">2011</td><td colspan="1" rowspan="1">Patient isolate (UHF<xref ref-type="table-fn" rid="tbl1fna">a</xref>)</td><td colspan="1" rowspan="1"><italic toggle="yes">blaOXA-23</italic></td></tr><tr><td colspan="1" rowspan="1"> AB 3: MDR and highly virulent</td><td colspan="1" rowspan="1">Rectal swab</td><td align="char" colspan="1" rowspan="1">2015</td><td colspan="1" rowspan="1">Patient isolate (UHF<xref ref-type="table-fn" rid="tbl1fna">a</xref>)</td><td colspan="1" rowspan="1"><italic toggle="yes">blaOXA-23</italic><xref ref-type="table-fn" rid="tbl1fnb">b</xref><sup>,</sup><xref ref-type="bibr" rid="bib15"><sup>15</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Klebsiella pneumoniae</italic></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> KP 1: wild-type <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic><xref ref-type="bibr" rid="bib14"><sup>14</sup></xref></td><td colspan="1" rowspan="1">Urine</td><td align="char" colspan="1" rowspan="1">1994</td><td colspan="1" rowspan="1">ATCC 700603</td><td colspan="1" rowspan="1"><italic toggle="yes">blaSHV-18</italic></td></tr><tr><td colspan="1" rowspan="1"> KP 2: MDR</td><td colspan="1" rowspan="1">Throat swab</td><td align="char" colspan="1" rowspan="1">2019</td><td colspan="1" rowspan="1">Patient isolate (UHF<xref ref-type="table-fn" rid="tbl1fna">a</xref>)</td><td colspan="1" rowspan="1"><italic toggle="yes">blaOXA-48</italic></td></tr><tr><td colspan="1" rowspan="1"> KP 3: MDR and highly virulent</td><td colspan="1" rowspan="1">Throat swab</td><td align="char" colspan="1" rowspan="1">2013</td><td colspan="1" rowspan="1">Patient isolate (UHF<xref ref-type="table-fn" rid="tbl1fna">a</xref>)</td><td colspan="1" rowspan="1"><italic toggle="yes">blaOXA-48</italic><xref ref-type="table-fn" rid="tbl1fnb">b</xref><sup>,</sup><xref ref-type="bibr" rid="bib16"><sup>16</sup></xref></td></tr></tbody></table><table-wrap-foot><fn><p>AB, <italic toggle="yes">Acinetobacter baumannii</italic>; KP, <italic toggle="yes">Klebsiella pneumoniae</italic>; MDR, multi-drug resistant.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0025">UHF = university hospital, Frankfurt am Main.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnb"><label>b</label><p id="ntpara0030">Highly virulent strains, associated with apoptosis<xref ref-type="bibr" rid="bib15"><sup>15</sup></xref> and high cytotoxicity.<xref ref-type="bibr" rid="bib16"><sup>16</sup></xref></p></fn></table-wrap-foot></table-wrap><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p><bold>Caco-2 cells infected 6 hours with <italic toggle="yes">A</italic></bold><bold><italic toggle="yes">baumannii</italic> or <italic toggle="yes">K</italic></bold><bold><italic toggle="yes">pneumoniae</italic>.</bold> (<italic toggle="yes">A</italic>) Double-fluorescence microscopy of Caco-2 cells following a 6-hour infection with <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> (AB) or <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic> (KP) strains. Extracellular bacteria are stained in <italic toggle="yes">green</italic> (Alexa-488), intracellular bacteria in <italic toggle="yes">orange</italic> (Alexa-647). The cytoskeleton is stained in <italic toggle="yes">red</italic> (TRITC-phalloidin), DNA and nuclei in <italic toggle="yes">blue</italic> (DAPI). Scale bar: 10 μm. Fluorescence microscopy analysis was performed with the microscope Zeiss Axio Imager 2 (Zeiss) equipped with a Spot RT3 camera (Diagnostic Instruments Inc) and operated by VisiView V.2.0.5 (Visitron Systems). Images were acquired with 63× objective. (<italic toggle="yes">B, C</italic>) Targeted metabolomics of analysis of Caco-2 cell-culture supernatants collected after 6-hour infection with <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> (<italic toggle="yes">B</italic>) or <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic> (<italic toggle="yes">C</italic>) strains. Controls included supernatants from uninfected Caco-2 cells and bacterial cultures incubated without host cells under identical conditions. Metabolomics profiling was performed on 2 biological replicates per condition, from 2 independent experiments, each consisting of 3 replicates pooled at the supernatant level. Loading plots from PCA models calculated on the relative concentrations of SCFAs in the reduced datasets are depicted. These plots reveal distinct metabolic shifts across experimental conditions, highlighting key metabolites contributing to group separation in PCA space. (<italic toggle="yes">D, E</italic>) Untargeted metabolomics analysis of Caco-2 cell-culture supernatants collected after 6-hour infection with <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> (<italic toggle="yes">D</italic>) or <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic> (<italic toggle="yes">E</italic>) strains. Controls included 6-hour incubated supernatants from uninfected Caco-2 cells and bacterial cultures incubated without host cells under identical conditions. Metabolomics profiling was performed on 2 biological replicates per condition, from 2 independent experiments, each consisting of 3 replicates pooled at the supernatant level. Loading plots from PCA models were generated based on the relative concentrations of metabolites annotated on level 1 and level 2a in the reduced datasets. These plots reveal distinct metabolic shifts across experimental conditions, highlighting key metabolites contributing to group separation in PCA space.</p></caption><graphic orientation="portrait" position="float" xlink:href="gr1.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></p></sec><sec id="sec1.2"><title>Identification of Key Metabolites From the Supernatants of Caco-2 Cells Infected With <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> or <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic></title><p id="p0050">To investigate the contribution of metabolites associated with gut bacterial infections to in vitro cytotoxicity, and their potential relevance to liver cell injury in ACLF, we performed metabolomics profiling of cell-free supernatants from Caco-2 cultures infected for 6 hours. For defining infection-driven metabolic changes, strict controls (supernatants from uninfected cells and bacteria cultured without host cells) were included (see <xref ref-type="sec" rid="sec3">Materials and Methods</xref>). All conditions were maintained under identical experimental parameters to ensure consistency and minimize confounding variables. Untargeted metabolomics analysis identified 1085 semi-polar metabolites. From these, 19 compounds from <italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic> infections and 15 from <italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic> infections annotated at levels 1 and 2a (indicating high structural confidence) were selected (<xref ref-type="fig" rid="fig1">Figure 1</xref><italic toggle="yes">D</italic> and <italic toggle="yes">E</italic>; <xref ref-type="table" rid="tbl2">Tables 2</xref> and <xref ref-type="table" rid="tbl3">3</xref>). Targeted metabolomics was also performed to quantify short-chain fatty acids (SCFAs) in the supernatants (<xref ref-type="fig" rid="fig1">Figure 1</xref><italic toggle="yes">B</italic> and <italic toggle="yes">C</italic>; <xref ref-type="table" rid="tbl3">Table 3</xref>). To compare metabolic shifts across conditions, clustered heatmaps of mean relative metabolite concentrations (to enhance interpretability) were generated (<xref ref-type="fig" rid="fig1">Figure 2</xref><italic toggle="yes">A</italic> and <italic toggle="yes">B</italic>; <xref ref-type="table" rid="tbl2">Tables 2</xref> and <xref ref-type="table" rid="tbl3">3</xref>). Values were row-normalized using Z-score to emphasize relative differences across conditions. Eight metabolites were consistently elevated during infection, also known to be associated with mitochondrial dysfunction, oxidative stress, and reactive oxygen species (ROS) production.<xref ref-type="bibr" rid="bib18">18</xref>, <xref ref-type="bibr" rid="bib19">19</xref>, <xref ref-type="bibr" rid="bib20">20</xref>, <xref ref-type="bibr" rid="bib21">21</xref>, <xref ref-type="bibr" rid="bib22">22</xref>, <xref ref-type="bibr" rid="bib23">23</xref>, <xref ref-type="bibr" rid="bib24">24</xref>, <xref ref-type="bibr" rid="bib25">25</xref>, <xref ref-type="bibr" rid="bib26">26</xref>, <xref ref-type="bibr" rid="bib27">27</xref>, <xref ref-type="bibr" rid="bib28">28</xref> For <italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic>, these included uridine (pyrimidine metabolism<xref ref-type="bibr" rid="bib18"><sup>18</sup></xref>), α-ketoglutarate (Krebs cycle<xref ref-type="bibr" rid="bib19"><sup>19</sup></xref>), indoleacetic acid (tryptophan metabolism<xref ref-type="bibr" rid="bib20"><sup>20</sup></xref>), and p-coumaric acid (aromatic amino acid biosynthesis<xref ref-type="bibr" rid="bib21"><sup>21</sup></xref>). For <italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic>, selected metabolites were desthiobiotin (biotin metabolism<xref ref-type="bibr" rid="bib22"><sup>22</sup></xref>), β-pinene (terpenoid pathway<xref ref-type="bibr" rid="bib23"><sup>23</sup></xref>), N8-acetylspermidine (polyamine metabolism<xref ref-type="bibr" rid="bib24"><sup>24</sup></xref>), and N-acetylglutamine (nitrogen compound biosynthesis<xref ref-type="bibr" rid="bib25"><sup>25</sup></xref>). These compounds were visualized as log2 fold changes, generated from mean relative abundances to enhance interpretability, relative to uninfected Caco-2 controls, (<xref ref-type="fig" rid="fig2">Figure 2</xref><italic toggle="yes">C–E</italic>; <xref ref-type="table" rid="tbl4">Table 4</xref>), and as log10 fold changes, generated from mean relative abundances to enhance interpretability, relative to uninfected Caco-2 cells controls (<xref ref-type="fig" rid="fig2">Figure 2</xref><italic toggle="yes">D–F</italic>; <xref ref-type="table" rid="tbl5">Table 5</xref>). Z-score normalization was applied to each row of log2 fold changes matrices prior to clustering, to enhance pattern recognition across conditions. Although metabolite profiles differed between <italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic> and <italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic>, they remained consistent across strains within each species (<xref ref-type="table" rid="tbl5">Table 5</xref>), indicating that species identity, rather than strain variability, predominantly governs these metabolic signatures during infection.<table-wrap id="tbl2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Mean Relative Abundance Values of <italic toggle="yes">A</italic><italic toggle="yes">baumannii-</italic>infected Caco-2 Cell Supernatants and Relative Controls</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Relative abundances: <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic>-infected cells</th><th colspan="1" rowspan="1">Caco-2-AB 1</th><th colspan="1" rowspan="1">Caco-2-AB 2</th><th colspan="1" rowspan="1">Caco-2-AB 3</th><th colspan="1" rowspan="1">AB 1</th><th colspan="1" rowspan="1">AB 2</th><th colspan="1" rowspan="1">AB 3</th><th colspan="1" rowspan="1">Caco-2</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Indole-3-acetic acid</td><td align="char" colspan="1" rowspan="1">76,607.00</td><td align="char" colspan="1" rowspan="1">82,786.50</td><td align="char" colspan="1" rowspan="1">73,767.50</td><td align="char" colspan="1" rowspan="1">109,041.50</td><td align="char" colspan="1" rowspan="1">128,144.50</td><td align="char" colspan="1" rowspan="1">113,697.50</td><td align="char" colspan="1" rowspan="1">42,808.50</td></tr><tr><td colspan="1" rowspan="1">2-hydroxyisocaproic acid</td><td align="char" colspan="1" rowspan="1">99,293.50</td><td align="char" colspan="1" rowspan="1">102,953.00</td><td align="char" colspan="1" rowspan="1">67,956.50</td><td align="char" colspan="1" rowspan="1">32,151.00</td><td align="char" colspan="1" rowspan="1">74,021.50</td><td align="char" colspan="1" rowspan="1">12,852.50</td><td align="char" colspan="1" rowspan="1">33,583.50</td></tr><tr><td colspan="1" rowspan="1">Cytosine</td><td align="char" colspan="1" rowspan="1">163,379.00</td><td align="char" colspan="1" rowspan="1">128,414.00</td><td align="char" colspan="1" rowspan="1">126,946.00</td><td align="char" colspan="1" rowspan="1">158,777.00</td><td align="char" colspan="1" rowspan="1">113,909.50</td><td align="char" colspan="1" rowspan="1">103,541.00</td><td align="char" colspan="1" rowspan="1">10,543.50</td></tr><tr><td colspan="1" rowspan="1">Kynurenine</td><td align="char" colspan="1" rowspan="1">23,687.50</td><td align="char" colspan="1" rowspan="1">14,363.50</td><td align="char" colspan="1" rowspan="1">21,772.00</td><td align="char" colspan="1" rowspan="1">−15,335.00</td><td align="char" colspan="1" rowspan="1">−15,168.50</td><td align="char" colspan="1" rowspan="1">−21,361.00</td><td align="char" colspan="1" rowspan="1">173,278.50</td></tr><tr><td colspan="1" rowspan="1">N8-acetylspermidine</td><td align="char" colspan="1" rowspan="1">60,349.54</td><td align="char" colspan="1" rowspan="1">58,447.54</td><td align="char" colspan="1" rowspan="1">64,967.54</td><td align="char" colspan="1" rowspan="1">−319.16</td><td align="char" colspan="1" rowspan="1">−976.62</td><td align="char" colspan="1" rowspan="1">−413.06</td><td align="char" colspan="1" rowspan="1">81,925.04</td></tr><tr><td colspan="1" rowspan="1">Xanthine</td><td align="char" colspan="1" rowspan="1">13,411.94</td><td align="char" colspan="1" rowspan="1">45,730.68</td><td align="char" colspan="1" rowspan="1">20,887.83</td><td align="char" colspan="1" rowspan="1">15,939.77</td><td align="char" colspan="1" rowspan="1">55,877.62</td><td align="char" colspan="1" rowspan="1">68,515.98</td><td align="char" colspan="1" rowspan="1">−1,050.61</td></tr><tr><td colspan="1" rowspan="1">Malic acid</td><td align="char" colspan="1" rowspan="1">54,096.50</td><td align="char" colspan="1" rowspan="1">43,971.00</td><td align="char" colspan="1" rowspan="1">24,628.00</td><td align="char" colspan="1" rowspan="1">35,189.50</td><td align="char" colspan="1" rowspan="1">27,676.00</td><td align="char" colspan="1" rowspan="1">22,813.50</td><td align="char" colspan="1" rowspan="1">14,484.00</td></tr><tr><td colspan="1" rowspan="1">Hexanoglycine</td><td align="char" colspan="1" rowspan="1">35,062.00</td><td align="char" colspan="1" rowspan="1">33,973.00</td><td align="char" colspan="1" rowspan="1">13,648.50</td><td align="char" colspan="1" rowspan="1">26,605.00</td><td align="char" colspan="1" rowspan="1">26,813.00</td><td align="char" colspan="1" rowspan="1">18,976.00</td><td align="char" colspan="1" rowspan="1">−4,628.50</td></tr><tr><td colspan="1" rowspan="1">Fumaric acid</td><td align="char" colspan="1" rowspan="1">16,213.37</td><td align="char" colspan="1" rowspan="1">17,248.87</td><td align="char" colspan="1" rowspan="1">6,929.87</td><td align="char" colspan="1" rowspan="1">24,026.37</td><td align="char" colspan="1" rowspan="1">16,163.37</td><td align="char" colspan="1" rowspan="1">11,706.87</td><td align="char" colspan="1" rowspan="1">−96.15</td></tr><tr><td colspan="1" rowspan="1">ß-pinene</td><td align="char" colspan="1" rowspan="1">22,975.74</td><td align="char" colspan="1" rowspan="1">24,865.24</td><td align="char" colspan="1" rowspan="1">30,445.74</td><td align="char" colspan="1" rowspan="1">8,853.24</td><td align="char" colspan="1" rowspan="1">13,727.74</td><td align="char" colspan="1" rowspan="1">44,205.74</td><td align="char" colspan="1" rowspan="1">16,043.24</td></tr><tr><td colspan="1" rowspan="1">N-acetyltirosine</td><td align="char" colspan="1" rowspan="1">3,595.50</td><td align="char" colspan="1" rowspan="1">2,232.50</td><td align="char" colspan="1" rowspan="1">2,990.50</td><td align="char" colspan="1" rowspan="1">16.00</td><td align="char" colspan="1" rowspan="1">1,899.86</td><td align="char" colspan="1" rowspan="1">1,856.00</td><td align="char" colspan="1" rowspan="1">319.49</td></tr><tr><td colspan="1" rowspan="1">3-phenyllactic acid</td><td align="char" colspan="1" rowspan="1">20,306.97</td><td align="char" colspan="1" rowspan="1">2,923.37</td><td align="char" colspan="1" rowspan="1">13,802.25</td><td align="char" colspan="1" rowspan="1">328.24</td><td align="char" colspan="1" rowspan="1">−7,211.90</td><td align="char" colspan="1" rowspan="1">5,965.14</td><td align="char" colspan="1" rowspan="1">−1,941.49</td></tr><tr><td colspan="1" rowspan="1">Acadesine</td><td align="char" colspan="1" rowspan="1">86,788.80</td><td align="char" colspan="1" rowspan="1">16,939.80</td><td align="char" colspan="1" rowspan="1">6,916.80</td><td align="char" colspan="1" rowspan="1">68,190.30</td><td align="char" colspan="1" rowspan="1">6,902.30</td><td align="char" colspan="1" rowspan="1">10,217.30</td><td align="char" colspan="1" rowspan="1">633.38</td></tr><tr><td colspan="1" rowspan="1">Desthiobiotin</td><td align="char" colspan="1" rowspan="1">220,537.00</td><td align="char" colspan="1" rowspan="1">51,984.00</td><td align="char" colspan="1" rowspan="1">54,720.00</td><td align="char" colspan="1" rowspan="1">192,553.50</td><td align="char" colspan="1" rowspan="1">47,925.00</td><td align="char" colspan="1" rowspan="1">81,939.50</td><td align="char" colspan="1" rowspan="1">−5,763.00</td></tr><tr><td colspan="1" rowspan="1">α-ketoglutaric acid</td><td align="char" colspan="1" rowspan="1">316,919.45</td><td align="char" colspan="1" rowspan="1">171,928.45</td><td align="char" colspan="1" rowspan="1">103,569.95</td><td align="char" colspan="1" rowspan="1">221,301.95</td><td align="char" colspan="1" rowspan="1">66,006.95</td><td align="char" colspan="1" rowspan="1">41,745.95</td><td align="char" colspan="1" rowspan="1">12,841.45</td></tr><tr><td colspan="1" rowspan="1">1-methyladenosine</td><td align="char" colspan="1" rowspan="1">257,051.68</td><td align="char" colspan="1" rowspan="1">220,336.18</td><td align="char" colspan="1" rowspan="1">245,406.68</td><td align="char" colspan="1" rowspan="1">1,487.50</td><td align="char" colspan="1" rowspan="1">790.95</td><td align="char" colspan="1" rowspan="1">759.44</td><td align="char" colspan="1" rowspan="1">243,730.18</td></tr><tr><td colspan="1" rowspan="1">Uridine</td><td align="char" colspan="1" rowspan="1">342,657.29</td><td align="char" colspan="1" rowspan="1">323,541.29</td><td align="char" colspan="1" rowspan="1">342,564.79</td><td align="char" colspan="1" rowspan="1">72,425.79</td><td align="char" colspan="1" rowspan="1">104,886.79</td><td align="char" colspan="1" rowspan="1">110,613.79</td><td align="char" colspan="1" rowspan="1">87,179.29</td></tr><tr><td colspan="1" rowspan="1">p-coumaric acid</td><td align="char" colspan="1" rowspan="1">11,587.50</td><td align="char" colspan="1" rowspan="1">297,981.00</td><td align="char" colspan="1" rowspan="1">343,301.50</td><td align="char" colspan="1" rowspan="1">4,872.50</td><td align="char" colspan="1" rowspan="1">282,136.00</td><td align="char" colspan="1" rowspan="1">411,424.50</td><td align="char" colspan="1" rowspan="1">69.50</td></tr><tr><td colspan="1" rowspan="1">Deoxycytidine</td><td align="char" colspan="1" rowspan="1">560,539.00</td><td align="char" colspan="1" rowspan="1">686,128.50</td><td align="char" colspan="1" rowspan="1">704,401.50</td><td align="char" colspan="1" rowspan="1">394,379.00</td><td align="char" colspan="1" rowspan="1">598,020.50</td><td align="char" colspan="1" rowspan="1">592,522.00</td><td align="char" colspan="1" rowspan="1">421,397.50</td></tr></tbody></table><table-wrap-foot><fn id="tspara0025"><p>NOTE. Relative abundances of altered metabolite patterns in Caco-2 cells infected for 6 hours with <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> compared with controls. Mean relative abundancies values of metabolite patterns from supernatants of Caco-2 cells infected for 6 hours with <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> strains, compared with controls: supernatants from uninfected Caco-2 cells, supernatants from bacteria grown without host cells, incubated 6 hours; see <xref ref-type="sec" rid="sec3">Material and Methods</xref>.</p></fn><fn id="tspara0030"><p>AB, <italic toggle="yes">Acinetobacter baumannii</italic>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Mean Relative Abundance Values of <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae-</italic>infected Caco-2 Cell Supernatants and Relative Controls</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Relative abundances: <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae-</italic>infected cells</th><th colspan="1" rowspan="1">Caco-2-KP 1</th><th colspan="1" rowspan="1">Caco-2-KP 2</th><th colspan="1" rowspan="1">Caco-2-KP 3</th><th colspan="1" rowspan="1">KP 1</th><th colspan="1" rowspan="1">KP 2</th><th colspan="1" rowspan="1">KP 3</th><th colspan="1" rowspan="1">Caco-2</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Desthiobiotin</td><td align="char" colspan="1" rowspan="1">375,065.00</td><td align="char" colspan="1" rowspan="1">97,751.00</td><td align="char" colspan="1" rowspan="1">151,521.50</td><td align="char" colspan="1" rowspan="1">322,553.00</td><td align="char" colspan="1" rowspan="1">75,995.00</td><td align="char" colspan="1" rowspan="1">123,463.50</td><td align="char" colspan="1" rowspan="1">−6,323.50</td></tr><tr><td colspan="1" rowspan="1">ß-pinene</td><td align="char" colspan="1" rowspan="1">427,480.67</td><td align="char" colspan="1" rowspan="1">96,016.67</td><td align="char" colspan="1" rowspan="1">336,344.67</td><td align="char" colspan="1" rowspan="1">189,991.67</td><td align="char" colspan="1" rowspan="1">−1,061.91</td><td align="char" colspan="1" rowspan="1">163,032.67</td><td align="char" colspan="1" rowspan="1">16,134.17</td></tr><tr><td colspan="1" rowspan="1">N8-acetylspermidine</td><td align="char" colspan="1" rowspan="1">117,209.02</td><td align="char" colspan="1" rowspan="1">177,477.52</td><td align="char" colspan="1" rowspan="1">485,331.52</td><td align="char" colspan="1" rowspan="1">57,127.02</td><td align="char" colspan="1" rowspan="1">159,467.52</td><td align="char" colspan="1" rowspan="1">445,061.52</td><td align="char" colspan="1" rowspan="1">89,521.02</td></tr><tr><td colspan="1" rowspan="1">SCFA: formic acid</td><td align="char" colspan="1" rowspan="1">16.72</td><td align="char" colspan="1" rowspan="1">16.31</td><td align="char" colspan="1" rowspan="1">17.76</td><td align="char" colspan="1" rowspan="1">14.10</td><td align="char" colspan="1" rowspan="1">11.95</td><td align="char" colspan="1" rowspan="1">14.81</td><td align="char" colspan="1" rowspan="1">0.14</td></tr><tr><td colspan="1" rowspan="1">SCFA: acetic acid</td><td align="char" colspan="1" rowspan="1">2.55</td><td align="char" colspan="1" rowspan="1">2.32</td><td align="char" colspan="1" rowspan="1">2.40</td><td align="char" colspan="1" rowspan="1">2.13</td><td align="char" colspan="1" rowspan="1">2.06</td><td align="char" colspan="1" rowspan="1">2.30</td><td align="char" colspan="1" rowspan="1">0.01</td></tr><tr><td colspan="1" rowspan="1">1-deoxyxylulose-5-phosphate</td><td align="char" colspan="1" rowspan="1">4,465.46</td><td align="char" colspan="1" rowspan="1">1,504.75</td><td align="char" colspan="1" rowspan="1">1,128.40</td><td align="char" colspan="1" rowspan="1">1,360.12</td><td align="char" colspan="1" rowspan="1">1,237.46</td><td align="char" colspan="1" rowspan="1">1,569.55</td><td align="char" colspan="1" rowspan="1">1,574.43</td></tr><tr><td colspan="1" rowspan="1">p-coumaric acid</td><td align="char" colspan="1" rowspan="1">2,627.00</td><td align="char" colspan="1" rowspan="1">164.00</td><td align="char" colspan="1" rowspan="1">81.00</td><td align="char" colspan="1" rowspan="1">1,700.50</td><td align="char" colspan="1" rowspan="1">−3,233.00</td><td align="char" colspan="1" rowspan="1">−2,814.50</td><td align="char" colspan="1" rowspan="1">−1,023.50</td></tr><tr><td colspan="1" rowspan="1">Uridine</td><td align="char" colspan="1" rowspan="1">−462.80</td><td align="char" colspan="1" rowspan="1">392.58</td><td align="char" colspan="1" rowspan="1">1,069.43</td><td align="char" colspan="1" rowspan="1">368.96</td><td align="char" colspan="1" rowspan="1">1,492.03</td><td align="char" colspan="1" rowspan="1">−362.95</td><td align="char" colspan="1" rowspan="1">96,931.98</td></tr><tr><td colspan="1" rowspan="1">Kynurenine</td><td align="char" colspan="1" rowspan="1">109,968.50</td><td align="char" colspan="1" rowspan="1">124,280.00</td><td align="char" colspan="1" rowspan="1">87,730.00</td><td align="char" colspan="1" rowspan="1">−8,681.50</td><td align="char" colspan="1" rowspan="1">−6,952.00</td><td align="char" colspan="1" rowspan="1">−27,219.50</td><td align="char" colspan="1" rowspan="1">189,709.50</td></tr><tr><td colspan="1" rowspan="1">Indole-3-acetic acid</td><td align="char" colspan="1" rowspan="1">35,101.50</td><td align="char" colspan="1" rowspan="1">30,911.00</td><td align="char" colspan="1" rowspan="1">46,024.00</td><td align="char" colspan="1" rowspan="1">225,674.50</td><td align="char" colspan="1" rowspan="1">188,950.50</td><td align="char" colspan="1" rowspan="1">196,827.50</td><td align="char" colspan="1" rowspan="1">24,665.00</td></tr><tr><td colspan="1" rowspan="1">Deoxycytidine</td><td align="char" colspan="1" rowspan="1">1,312.00</td><td align="char" colspan="1" rowspan="1">1,143.00</td><td align="char" colspan="1" rowspan="1">−5,100.00</td><td align="char" colspan="1" rowspan="1">5,295.50</td><td align="char" colspan="1" rowspan="1">968.00</td><td align="char" colspan="1" rowspan="1">−2,393.00</td><td align="char" colspan="1" rowspan="1">486,259.00</td></tr><tr><td colspan="1" rowspan="1">Cytodine</td><td align="char" colspan="1" rowspan="1">1,637.97</td><td align="char" colspan="1" rowspan="1">1,787.97</td><td align="char" colspan="1" rowspan="1">−185.53</td><td align="char" colspan="1" rowspan="1">−2,115.67</td><td align="char" colspan="1" rowspan="1">−555.82</td><td align="char" colspan="1" rowspan="1">−1,779.03</td><td align="char" colspan="1" rowspan="1">379,416.97</td></tr><tr><td colspan="1" rowspan="1">1-methyladenosine</td><td align="char" colspan="1" rowspan="1">176,046.93</td><td align="char" colspan="1" rowspan="1">198,623.43</td><td align="char" colspan="1" rowspan="1">187,088.93</td><td align="char" colspan="1" rowspan="1">−710.43</td><td align="char" colspan="1" rowspan="1">−240.58</td><td align="char" colspan="1" rowspan="1">−1,349.88</td><td align="char" colspan="1" rowspan="1">303,978.93</td></tr><tr><td colspan="1" rowspan="1">N-acetylglutamine</td><td align="char" colspan="1" rowspan="1">855,019.00</td><td align="char" colspan="1" rowspan="1">552,261.00</td><td align="char" colspan="1" rowspan="1">652,604.00</td><td align="char" colspan="1" rowspan="1">532,288.00</td><td align="char" colspan="1" rowspan="1">304,535.00</td><td align="char" colspan="1" rowspan="1">397,813.00</td><td align="char" colspan="1" rowspan="1">4,348.50</td></tr><tr><td colspan="1" rowspan="1">Fumaric acid</td><td align="char" colspan="1" rowspan="1">498,206.91</td><td align="char" colspan="1" rowspan="1">452,212.91</td><td align="char" colspan="1" rowspan="1">644,051.41</td><td align="char" colspan="1" rowspan="1">485,621.91</td><td align="char" colspan="1" rowspan="1">378,458.91</td><td align="char" colspan="1" rowspan="1">579,523.91</td><td align="char" colspan="1" rowspan="1">−1,225.90</td></tr></tbody></table><table-wrap-foot><fn id="tspara0040"><p>NOTE. Relative abundances of altered metabolite patterns in Caco-2 cells infected for 6 hours with <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic> compared with controls. Mean relative abundancy values of metabolite patterns from supernatants of Caco-2 cells infected for 6 hours with <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic> strains, compared with controls: supernatants from uninfected Caco-2 cells, supernatants from bacteria grown without host cells, incubated 6 hours; see <xref ref-type="sec" rid="sec3">Material and Methods</xref>.</p></fn><fn id="tspara0045"><p>KP, <italic toggle="yes">Klebsiella pneumoniae</italic>; SCFA, short-chain fatty acid.</p></fn></table-wrap-foot></table-wrap><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p><bold>Altered metabolites patterns in Caco-2 cells infected 6 hours with A</bold><bold>baumannii or K</bold><bold>pneumoniae compared with controls.</bold> (<italic toggle="yes">A</italic> and <italic toggle="yes">B</italic>) Clustered heat map of mean relative metabolite abundances in supernatants of Caco-2 cells infected for 6 hours with <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> (AB) or <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic> (KP) strains, respectively, to enhance interpretability. To identify metabolites increased due to bacterial infections, controls included supernatants from uninfected Caco-2 cells and bacterial cultures incubated without host cells for 6 hours under identical conditions. Metabolomics profiling was performed on 2 biological replicates per condition, from 2 independent experiments, each consisting of 3 replicates pooled at the supernatant level. Values were row-normalized using Z-score to emphasize relative differences across conditions. For further details, see <xref ref-type="table" rid="tbl2">Tables 2</xref> and <xref ref-type="table" rid="tbl3">3</xref>. (<italic toggle="yes">C</italic> and <italic toggle="yes">E</italic>) Clustered heatmaps showing log2-fold changes in selected metabolites levels, generated from mean relative abundances, following 6-hour infections of Caco-2 cells with <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> (AB) or <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic> (KP), respectively. Fold changes were calculated by normalizing metabolite intensities to those in uninfected Caco-2 cell controls incubated under identical conditions, enabling identification of infection-associated metabolic increases. Z-score normalization was applied to each row of log2 fold changes matrices prior to clustering, to enhance pattern recognition across conditions. For further details, see <xref ref-type="table" rid="tbl4">Table 4</xref>. (<italic toggle="yes">D</italic> and <italic toggle="yes">F</italic>) Clustered heatmaps showing log10-fold changes in selected metabolites levels, generated from mean relative abundances, following 6-hour infections of Caco-2 cells with <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> (AB) or <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic> (KP), respectively. Fold changes were calculated by normalizing metabolite intensities to those in uninfected Caco-2 cell controls incubated under identical conditions, enabling identification of infection associated metabolic increases. For further details, see <xref ref-type="table" rid="tbl5">Table 5</xref>.</p></caption><graphic orientation="portrait" position="float" xlink:href="gr2.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><table-wrap id="tbl4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Log2-Fold Change of Metabolites of Interest in <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> or <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae-</italic>infected Caco-2 Cell Supernatants Compared With Uninfected Caco-2 Cells Control, Calculated From Mean Metabolite Abundances</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Log2 fold change</th><th colspan="1" rowspan="1">Caco-2-AB 1</th><th colspan="1" rowspan="1">Caco-2-AB 2</th><th colspan="1" rowspan="1">Caco-2-AB 3</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic>-infected cells</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> Indole-3-acetic acid</td><td align="char" colspan="1" rowspan="1">0.84</td><td align="char" colspan="1" rowspan="1">0.95</td><td align="char" colspan="1" rowspan="1">0.79</td></tr><tr><td colspan="1" rowspan="1"> Uridine</td><td align="char" colspan="1" rowspan="1">1.97</td><td align="char" colspan="1" rowspan="1">1.89</td><td align="char" colspan="1" rowspan="1">1.97</td></tr><tr><td colspan="1" rowspan="1"> α-ketoglutarate</td><td align="char" colspan="1" rowspan="1">4.63</td><td align="char" colspan="1" rowspan="1">3.74</td><td align="char" colspan="1" rowspan="1">3.01</td></tr><tr><td colspan="1" rowspan="1"> p-coumaric acid</td><td align="char" colspan="1" rowspan="1">7.38</td><td align="char" colspan="1" rowspan="1">12.07</td><td align="char" colspan="1" rowspan="1">12.27</td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Caco-2-KP 1</td><td colspan="1" rowspan="1">Caco-2-KP 2</td><td colspan="1" rowspan="1">Caco-2-KP 3</td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic>-infected cells</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> N-acetylglutamine</td><td align="char" colspan="1" rowspan="1">7.62</td><td align="char" colspan="1" rowspan="1">6.99</td><td align="char" colspan="1" rowspan="1">7.23</td></tr><tr><td colspan="1" rowspan="1"> ß-pinene</td><td align="char" colspan="1" rowspan="1">4.73</td><td align="char" colspan="1" rowspan="1">2.57</td><td align="char" colspan="1" rowspan="1">4.38</td></tr><tr><td colspan="1" rowspan="1"> N8-acetylspermidine</td><td align="char" colspan="1" rowspan="1">0.39</td><td align="char" colspan="1" rowspan="1">0.99</td><td align="char" colspan="1" rowspan="1">2.44</td></tr><tr><td colspan="1" rowspan="1"> Desthiobiotin</td><td align="char" colspan="1" rowspan="1">21.84</td><td align="char" colspan="1" rowspan="1">19.90</td><td align="char" colspan="1" rowspan="1">20.53</td></tr></tbody></table><table-wrap-foot><fn id="tspara0055"><p>NOTE. Log2-fold change values of selected metabolites derived from 6-hour Caco-2 infections with <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> or <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic> strains, normalized to levels in uninfected Caco-2 cell controls incubated under identical conditions, calculated from mean metabolite abundances.</p></fn><fn id="tspara0060"><p>AB, <italic toggle="yes">Acinetobacter baumannii</italic>; KP, <italic toggle="yes">Klebsiella pneumoniae</italic>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Log10-Fold Change of Metabolites of Interest in <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> or <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic>-infected Caco-2 Cell Supernatants Compared With Uninfected Caco-2 Cells Control, Calculated From Mean Metabolite Abundances</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Log10FC metabolites</th><th colspan="1" rowspan="1">Caco-2-AB 1</th><th colspan="1" rowspan="1">Caco-2-AB 2</th><th colspan="1" rowspan="1">Caco-2-AB 3</th><th colspan="1" rowspan="1">Mean Caco-2 AB</th><th colspan="1" rowspan="1">SD Caco-2 AB</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic>-infected cells</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> Indole-3-acetic acid</td><td align="char" colspan="1" rowspan="1">0.25</td><td align="char" colspan="1" rowspan="1">0.29</td><td align="char" colspan="1" rowspan="1">0.24</td><td align="char" colspan="1" rowspan="1">0.26</td><td align="char" colspan="1" rowspan="1">0.026</td></tr><tr><td colspan="1" rowspan="1"> Uridine</td><td align="char" colspan="1" rowspan="1">0.59</td><td align="char" colspan="1" rowspan="1">0.57</td><td align="char" colspan="1" rowspan="1">0.59</td><td align="char" colspan="1" rowspan="1">0.59</td><td align="char" colspan="1" rowspan="1">0.014</td></tr><tr><td colspan="1" rowspan="1"> α-ketoglutarate</td><td align="char" colspan="1" rowspan="1">1.39</td><td align="char" colspan="1" rowspan="1">1.13</td><td align="char" colspan="1" rowspan="1">0.91</td><td align="char" colspan="1" rowspan="1">1.14</td><td align="char" colspan="1" rowspan="1">0.243</td></tr><tr><td colspan="1" rowspan="1"> p-coumaric acid</td><td align="char" colspan="1" rowspan="1">2.22</td><td align="char" colspan="1" rowspan="1">3.63</td><td align="char" colspan="1" rowspan="1">3.69</td><td align="char" colspan="1" rowspan="1">3.18</td><td align="char" colspan="1" rowspan="1">0.832</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1">Caco-2-KP 1</th><th colspan="1" rowspan="1">Caco-2-KP 2</th><th colspan="1" rowspan="1">Caco-2-KP 3</th><th colspan="1" rowspan="1">Mean Caco-2 KP</th><th colspan="1" rowspan="1">SD Caco-2 KP</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><italic toggle="yes">K</italic><italic toggle="yes">pneumoniae-</italic>infected cells</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> N-acetylglutamine</td><td align="char" colspan="1" rowspan="1">2.29</td><td align="char" colspan="1" rowspan="1">2.10</td><td align="char" colspan="1" rowspan="1">2.18</td><td align="char" colspan="1" rowspan="1">2.19</td><td align="char" colspan="1" rowspan="1">0.096</td></tr><tr><td colspan="1" rowspan="1"> ß-pinene</td><td align="char" colspan="1" rowspan="1">1.42</td><td align="char" colspan="1" rowspan="1">0.77</td><td align="char" colspan="1" rowspan="1">1.32</td><td align="char" colspan="1" rowspan="1">1.17</td><td align="char" colspan="1" rowspan="1">0.348</td></tr><tr><td colspan="1" rowspan="1"> N8-acetylspermidine</td><td align="char" colspan="1" rowspan="1">0.12</td><td align="char" colspan="1" rowspan="1">0.30</td><td align="char" colspan="1" rowspan="1">0.73</td><td align="char" colspan="1" rowspan="1">0.38</td><td align="char" colspan="1" rowspan="1">0.317</td></tr><tr><td colspan="1" rowspan="1"> Desthiobiotin</td><td align="char" colspan="1" rowspan="1">6.57</td><td align="char" colspan="1" rowspan="1">5.99</td><td align="char" colspan="1" rowspan="1">6.18</td><td align="char" colspan="1" rowspan="1">6.25</td><td align="char" colspan="1" rowspan="1">0.298</td></tr></tbody></table><table-wrap-foot><fn id="tspara0070"><p>NOTE. Log10-fold change of selected metabolites of interest derived from 6-hour Caco-2 infections with <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> or <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic> strains, normalized to levels in uninfected Caco-2 cell controls incubated under identical conditions, highlighting the association between metabolites and bacterial strains infections, calculated from mean metabolite abundances. Mean and standard deviations are depicted.</p></fn><fn id="tspara0075"><p>AB, <italic toggle="yes">Acinetobacter baumannii</italic>; KP, <italic toggle="yes">Klebsiella pneumoniae</italic>; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap></p><p id="p0055">Metabolite origin was inferred through comparative analysis of relative abundances across the 3 experimental conditions described above. In <italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic> infection experiments (<xref ref-type="table" rid="tbl2">Table 2</xref>), α-ketoglutarate and p-coumaric acid were highly secreted by bacteria grown without Caco-2 cells, with lower levels detected in uninfected Caco-2 cells and predominantly elevated levels in supernatants from infected Caco-2 cells, indicating a bacterial origin amplified during infection. Uridine was similarly secreted by both host cells and bacteria, but its levels were substantially higher in infected conditions, suggesting a synergistic contribution. Indoleacetic acid was primarily of bacterial origin, with lower levels in uninfected cells and elevated but slightly lower values in infected supernatants. In <italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic> infection experiments (<xref ref-type="table" rid="tbl3">Table 3</xref>), desthiobiotin, β-pinene, N8-acetylspermidine, and N-acetylglutamine were highly secreted by bacteria (except for ß-pinene in KP 2). These metabolites were lower in uninfected Caco-2 supernatants and showed predominant abundance during Caco-2 cell infections. These results indicate that, although certain metabolites, such as uridine, may reflect a host-derived response, the majority of metabolic signatures are of bacterial origin and amplified during host-pathogen interaction. This approach provides strong evidence for metabolite origin and supports the biological relevance of the infection-associated metabolic profiles observed.</p></sec><sec id="sec1.3"><title>Supernatants From Caco-2 Cells Infected With <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> or <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic> Exhibit Cytotoxic Effects on HepG2 Cells</title><p id="p0060">In vivo, metabolites from the gut are transported to the liver via the portal vein.<xref ref-type="bibr" rid="bib3">3</xref>, <xref ref-type="bibr" rid="bib4">4</xref>, <xref ref-type="bibr" rid="bib5">5</xref> To simulate this physiological translocation, HepG2 liver cells were exposed to 5 concentrations of supernatants from 6-hour infected Caco-2 cells (see <xref ref-type="sec" rid="sec3">Materials and Methods</xref>). This exposure led to a dose-dependent reduction in HepG2 viability across all time points (<xref ref-type="fig" rid="fig3">Figure 3</xref><italic toggle="yes">A</italic> and <italic toggle="yes">B</italic>) (<italic toggle="yes">P</italic> &lt; .0001). Equivalent concentrations of control supernatants from uninfected Caco-2 cells and bacteria cultured without host cells (6-hour incubation) showed no cytotoxicity. These findings suggest that hepatotoxicity originates from infection-specific factors in the supernatants of infected Caco-2 cells that seem to contain a cytotoxic mixture of the previously identified metabolites.<fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p><bold>Viability of HepG2 cells after stimulation with conditioned media derived from Caco-2 cells infected for 6 hours with (<italic toggle="yes">A</italic>) <italic toggle="yes">A</italic></bold><bold><italic toggle="yes">baumannii</italic> (AB) or (<italic toggle="yes">B</italic>) <italic toggle="yes">K</italic></bold><bold><italic toggle="yes">pneumoniae</italic> (KP) strains compared with controls.</bold> Conditioned media from 6-hour infected-Caco-2 cells were added to HepG2 cultures at 5 different concentrations (100%, 50%, 25%, 10%, and 5%; diluted in fresh medium). Controls included conditioned media from uninfected Caco-2 cells, and from bacterial cultures incubated without host cells, were both prepared under identical 6-hour conditions, and added at matching concentrations. Untreated HepG2 cells served as negative controls. Viability of HepG2 cells was assessed via XTT assays after for 2, 3, and 4 hours of exposure. Bar charts depict results with supernatants taken from infections. <italic toggle="yes">Black</italic>, reference strains; <italic toggle="yes">gray</italic>, MDR strains; <italic toggle="yes">white</italic>, highly virulent strains. <italic toggle="yes">Light gray bars</italic> in the background represent control conditions. Each condition was tested in triplicates across 3 independent experiments. Values are means ± SD. All values differed from the appropriate controls with a statistical significance of <italic toggle="yes">P</italic> &lt; .0001, determined using 2-way ANOVA analysis (not shown in graphics to maintain readability, given the extensive number of conditions considered).</p></caption><graphic orientation="portrait" position="float" xlink:href="gr3.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></p></sec><sec id="sec1.4"><title>Metabolites Selected From Supernatants of Caco-2 Cells Infected With <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> or <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic> Are Cytotoxic to HepG2-Cells</title><p id="p0065">To elucidate the hepatotoxic effects of conditioned media, 8 metabolites identified in 6-hour infected-Caco-2 supernatants were selected for further analysis: α-ketoglutarate, uridine, p-coumaric acid, and indoleacetic acid from <italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic> infections; and desthiobiotin, β-pinene, N8-acetylspermidine, and N-acetylglutamine from <italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic>. HepG2 cells were exposed to 2 metabolite mixtures (each comprising the 4 respective metabolites associated with either bacterium), as well as to the individual compounds (all tested at 4 concentrations). Strict dimethyl sulfoxide (DMSO) solvent controls at matching concentrations were included to exclude matrix effects. A dose-dependent reduction in HepG2 viability was observed as early as 2 hours post-exposure for both individual compounds and mixtures (<xref ref-type="fig" rid="fig4">Figure 4</xref><italic toggle="yes">A</italic> and <italic toggle="yes">B</italic>) (<italic toggle="yes">P</italic> &lt; .0001), whereas DMSO controls had no effect. Notably, both mixtures induced stronger cytotoxicity than individual metabolites, suggesting additive detrimental effects, most pronounced with the <italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic>-derived compound mixture.<fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p><bold>Viability of HepG2 cells following stimulation with selected metabolites identified from Caco-2 cells infected 6 hours with (<italic toggle="yes">A</italic>) <italic toggle="yes">A</italic></bold><bold><italic toggle="yes">baumannii</italic> or (<italic toggle="yes">B</italic>) <italic toggle="yes">K</italic></bold><bold><italic toggle="yes">pneumoniae</italic> strains compared with controls.</bold> HepG2 cells were exposed to individual metabolites and corresponding compound mixtures: α-ketoglutarate, uridine, p-coumaric acid, and indoleacetic acid (from <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> infected-Caco-2 cells); desthiobiotin, β-pinene, N8-acetylspermidine, and N-acetylglutamine (from <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic> infected-Caco-2 cells). Each compound or mixture was applied at concentrations of 50, 100, 250, and 500 μg/mL diluted in fresh medium. Controls included HepG2 cells treated with DMSO (solvent control) at matching concentrations used for metabolite preparation, shown in <italic toggle="yes">light gray bars</italic> in the background. Untreated HepG2 cells served as negative control. Cell viability was evaluated using XTT assays after 2, 3, and 4 hours of exposure. Each condition was tested in triplicates across 3 independent experiments. Values are means ± SD. All values differed from the appropriate controls with a statistical significance of <italic toggle="yes">P</italic> &lt; .0001, determined using 2-way ANOVA analysis (not shown in graphics to maintain readability, given the extensive number of conditions considered).</p></caption><graphic orientation="portrait" position="float" xlink:href="gr4.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></p></sec><sec id="sec1.5"><title>Ex Vivo Validation of Infection-associated Metabolites in Sera From Patients With AD and ACLF</title><p id="p0070">To investigate the potential association between hepatotoxic metabolites identified in vitro and ACLF, we performed ex vivo metabolomics analysis on serum samples from 2 independent patient cohorts. The Frankfurt cohort included healthy controls and sera from patients with ACLF of alcoholic origin (<xref ref-type="table" rid="tbl6">Table 6</xref>), whereas the Bonn/Münster cohort consisted of sera from patients with acutely decompensated liver cirrhosis, stratified by Model of End-stage Liver Disease (MELD) score (≤10 or &gt;10) to assess disease severity (<xref ref-type="table" rid="tbl7">Table 7</xref>).<table-wrap id="tbl6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Patient Characteristics of the Frankfurt Cohort (N = 20)</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Characteristics</th><th colspan="1" rowspan="1">All patients (N = 20)</th><th colspan="1" rowspan="1">MELD ≤30 (n = 10)</th><th colspan="1" rowspan="1">MELD &gt;30 (n = 10)</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Age, <italic toggle="yes">y</italic></td><td colspan="1" rowspan="1">53.50 (45.75–58.00) (20)</td><td colspan="1" rowspan="1">55.00 (44.50–60.00) (10)</td><td colspan="1" rowspan="1">50.00 (46.25–55.75) (10)</td><td align="char" colspan="1" rowspan="1">1.000</td></tr><tr><td colspan="1" rowspan="1">Sex</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">1.000</td></tr><tr><td colspan="1" rowspan="1"> Female</td><td colspan="1" rowspan="1">7 (35.0%) (20)</td><td colspan="1" rowspan="1">3 (30.0%) (10)</td><td colspan="1" rowspan="1">4 (40.0%) (10)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> Male</td><td colspan="1" rowspan="1">13 (65.0%) (20)</td><td colspan="1" rowspan="1">7 (70.0%) (10)</td><td colspan="1" rowspan="1">6 (60.0%) (10)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">AST, <italic toggle="yes">IU/L</italic></td><td colspan="1" rowspan="1">115.00 (80.75–249.25) (20)</td><td colspan="1" rowspan="1">98.00 (70.25–365.00) (10)</td><td colspan="1" rowspan="1">140.00 (97.25–184.25) (10)</td><td align="char" colspan="1" rowspan="1">.393</td></tr><tr><td colspan="1" rowspan="1">ALT, <italic toggle="yes">IU/L</italic></td><td colspan="1" rowspan="1">55.50 (34.50–142.50) (20)</td><td colspan="1" rowspan="1">49.50 (33.50–112.00) (10)</td><td colspan="1" rowspan="1">61.50 (41.25–171.50) (10)</td><td align="char" colspan="1" rowspan="1">.496</td></tr><tr><td colspan="1" rowspan="1">CRP, <italic toggle="yes">mg/dL</italic></td><td colspan="1" rowspan="1">3.18 (2.00–4.76) (20)</td><td colspan="1" rowspan="1">3.29 (1.49–4.58) (10)</td><td colspan="1" rowspan="1">2.78 (2.11–4.81) (10)</td><td align="char" colspan="1" rowspan="1">.821</td></tr><tr><td colspan="1" rowspan="1">WBC, <italic toggle="yes">× 1000/μL</italic></td><td colspan="1" rowspan="1">13.29 (9.06–17.31) (20)</td><td colspan="1" rowspan="1">14.88 (11.39–19.31) (10)</td><td colspan="1" rowspan="1">11.52 (8.82–13.97) (10)</td><td align="char" colspan="1" rowspan="1">.247</td></tr><tr><td colspan="1" rowspan="1">INR (median/range/sample size)</td><td colspan="1" rowspan="1">2.39 (1.84–2.54) (20)</td><td colspan="1" rowspan="1">1.88 (1.45–2.17) (10)</td><td colspan="1" rowspan="1">2.55 (2.52–2.95) (10)</td><td align="char" colspan="1" rowspan="1">.001</td></tr><tr><td colspan="1" rowspan="1">Child-Pugh class</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">1.000</td></tr><tr><td colspan="1" rowspan="1"> Child B</td><td colspan="1" rowspan="1">1 (5.0%) (20)</td><td colspan="1" rowspan="1">1 (10.0%) (10)</td><td colspan="1" rowspan="1">0 (0.0%) (10)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> Child C</td><td colspan="1" rowspan="1">19 (95.0%) (20)</td><td colspan="1" rowspan="1">9 (90.0%) (10)</td><td colspan="1" rowspan="1">10 (100.0%) (10)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Indication for TIPS</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">.474</td></tr><tr><td colspan="1" rowspan="1"> NA</td><td colspan="1" rowspan="1">17 (85.0%) (20)</td><td colspan="1" rowspan="1">9 (90.0%) (10)</td><td colspan="1" rowspan="1">8 (80.0%) (10)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> Variceal bleeding</td><td colspan="1" rowspan="1">2 (10.0%) (20)</td><td colspan="1" rowspan="1">0 (0.0%) (10)</td><td colspan="1" rowspan="1">2 (20.0%) (10)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> Refractory ascites</td><td colspan="1" rowspan="1">1 (5.0%) (20)</td><td colspan="1" rowspan="1">1 (10.0%) (10)</td><td colspan="1" rowspan="1">0 (0.0%) (10)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">CLIF-C ACLF score</td><td colspan="1" rowspan="1">54.43 (46.36–59.07) (20)</td><td colspan="1" rowspan="1">51.29 (45.16–56.61) (10)</td><td colspan="1" rowspan="1">54.57 (50.46–62.65) (10)</td><td align="char" colspan="1" rowspan="1">.436</td></tr><tr><td colspan="1" rowspan="1">ACLF grade</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">.195</td></tr><tr><td colspan="1" rowspan="1"> Grade 1</td><td colspan="1" rowspan="1">6 (30.0%) (20)</td><td colspan="1" rowspan="1">5 (50.0%) (10)</td><td colspan="1" rowspan="1">1 (10.0%) (10)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> Grade 2</td><td colspan="1" rowspan="1">9 (45.0%) (20)</td><td colspan="1" rowspan="1">3 (30.0%) (10)</td><td colspan="1" rowspan="1">6 (60.0%) (10)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> Grade 3</td><td colspan="1" rowspan="1">5 (25.0%) (20)</td><td colspan="1" rowspan="1">2 (20.0%) (10)</td><td colspan="1" rowspan="1">3 (30.0%) (10)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Etiology of cirrhosis</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">NA</td></tr><tr><td colspan="1" rowspan="1"> Alcohol</td><td colspan="1" rowspan="1">20 (100.0%) (20)</td><td colspan="1" rowspan="1">10 (100.0%) (10)</td><td colspan="1" rowspan="1">10 (100.0%) (10)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Bacterial infections</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">1.000</td></tr><tr><td colspan="1" rowspan="1"> No</td><td colspan="1" rowspan="1">5 (25.0%) (20)</td><td colspan="1" rowspan="1">3 (30.0%) (10)</td><td colspan="1" rowspan="1">2 (20.0%) (10)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> Yes</td><td colspan="1" rowspan="1">15 (75.0%) (20)</td><td colspan="1" rowspan="1">7 (70.0%) (10)</td><td colspan="1" rowspan="1">8 (80.0%) (10)</td><td colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tspara0085"><p>NOTE. Data are presented as number (%) (sample size) or median (range) (sample size).</p></fn><fn id="tspara0090"><p>ACLF, acute-on-chronic liver failure; ALT, alanine aminotransaminase; AST, aspartate aminotransaminase; CRP, C-reactive protein; INR, International Normalized Ratio; MELD, Model of End-stage Liver Disease; NA, not available; TIPS, transjugular intrahepatic portosystemic shunt; WBC, white blood cell count.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl7" orientation="portrait" position="float"><label>Table 7</label><caption><p>Patient Characteristics of the Bonn/Münster Cohort (N = 32)</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="2">Characteristics</th><th colspan="1" rowspan="1">MELD ≤10<hr/></th><th colspan="1" rowspan="1">MELD &gt;10<hr/></th><th colspan="1" rowspan="2"><italic toggle="yes">P</italic> value</th></tr><tr><th colspan="1" rowspan="1">n = 13</th><th colspan="1" rowspan="1">n = 19</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Age, <italic toggle="yes">y</italic></td><td align="char" colspan="1" rowspan="1">56 (34–81)</td><td align="char" colspan="1" rowspan="1">59 (51–72)</td><td align="char" colspan="1" rowspan="1">.166</td></tr><tr><td colspan="1" rowspan="1">Male sex</td><td align="char" colspan="1" rowspan="1">5 (38.5)</td><td align="char" colspan="1" rowspan="1">13 (68.4)</td><td align="char" colspan="1" rowspan="1">.188</td></tr><tr><td colspan="1" rowspan="1">AST, <italic toggle="yes">IU/L</italic></td><td align="char" colspan="1" rowspan="1">30.5 (±71.4)</td><td align="char" colspan="1" rowspan="1">46.0 (±26.0)</td><td align="char" colspan="1" rowspan="1">.128</td></tr><tr><td colspan="1" rowspan="1">ALT, <italic toggle="yes">IU/L</italic></td><td align="char" colspan="1" rowspan="1">27.0 (±61.0)</td><td align="char" colspan="1" rowspan="1">20.0 (±15.6)</td><td align="char" colspan="1" rowspan="1">.290</td></tr><tr><td colspan="1" rowspan="1">CRP, <italic toggle="yes">mg/dL</italic></td><td align="char" colspan="1" rowspan="1">5.5 (±29.0)</td><td align="char" colspan="1" rowspan="1">15.3 (±15.4)</td><td align="char" colspan="1" rowspan="1">.301</td></tr><tr><td colspan="1" rowspan="1">WBC, <italic toggle="yes">× 1000/μL</italic></td><td align="char" colspan="1" rowspan="1">8.7 (±7.6)</td><td align="char" colspan="1" rowspan="1">6.7 (±3.0)</td><td align="char" colspan="1" rowspan="1">.514</td></tr><tr><td colspan="1" rowspan="1">INR</td><td align="char" colspan="1" rowspan="1">1.1 (±0.2)</td><td align="char" colspan="1" rowspan="1">1.2 (±0.3)</td><td align="char" colspan="1" rowspan="1">.184</td></tr><tr><td colspan="1" rowspan="1">Child-Pugh class</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> Child A</td><td align="char" colspan="1" rowspan="1">8 (61.5)</td><td colspan="1" rowspan="1">0.0</td><td align="char" colspan="1" rowspan="1">.0001</td></tr><tr><td colspan="1" rowspan="1"> Child B</td><td align="char" colspan="1" rowspan="1">4 (30.8)</td><td align="char" colspan="1" rowspan="1">16 (84.2)</td><td align="char" colspan="1" rowspan="1">.0035</td></tr><tr><td colspan="1" rowspan="1"> Child C</td><td colspan="1" rowspan="1">0.0</td><td align="char" colspan="1" rowspan="1">2 (10.5)</td><td align="char" colspan="1" rowspan="1">.502</td></tr><tr><td colspan="1" rowspan="1">Indication for TIPS (repeated or high-risk variceal bleeding/refractory or recurrent ascites/others<xref ref-type="table-fn" rid="tbl7fna">a</xref>)</td><td colspan="1" rowspan="1">4/6/3</td><td colspan="1" rowspan="1">2/16/1</td><td align="char" colspan="1" rowspan="1">.072</td></tr><tr><td colspan="1" rowspan="1">CLIF C scores, median (±SD; no.)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> CLIF C AD</td><td align="char" colspan="1" rowspan="1">44.5 (±6.6; 12)</td><td align="char" colspan="1" rowspan="1">49.0 (±5.6; 13)</td><td align="char" colspan="1" rowspan="1">.209</td></tr><tr><td colspan="1" rowspan="1"> CLIF C ACLF</td><td align="char" colspan="1" rowspan="1">35.0 (±0.0; 1)</td><td align="char" colspan="1" rowspan="1">42.5 (±3.1; 6)</td><td align="char" colspan="1" rowspan="1">.207</td></tr></tbody></table><table-wrap-foot><fn id="tspara0100"><p>NOTE. Data are presented as number (%), median (range), or mean ± standard deviataion.</p></fn><fn id="tspara0105"><p>ACLF, acute-on-chronic liver failure; ALT, alanine aminotransaminase; AST, aspartate aminotransaminase; CRP, C-reactive protein; INR, International Normalized Ratio; MELD, Model of End-stage Liver Disease; NA, not available; TIPS, transjugular intrahepatic portosystemic shunt; WBC, white blood cell count.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl7fna"><label>a</label><p id="ntpara0035">Portal vein thrombosis, TIPS dysfunction.</p></fn></table-wrap-foot></table-wrap></p><sec id="sec1.5.1"><title>Frankfurt cohort</title><p id="p0075">In the Frankfurt cohort, semi-quantitative analysis was performed on sera from patients with ACLF and healthy controls using high-resolution mass spectrometry. To ensure better inter-study comparability, all results were normalized to the Standard Reference Material (SRM) 1950 National Institute of Standards and Technology (NIST) reference material, adding consistency and reliability to the data. Among the 8 hepatotoxic metabolites identified through in vitro experiments (see above), α-ketoglutarate and N-acetylglutamine were also significantly elevated in patient serum samples, underscoring their translational and biological relevance. In particular, α-ketoglutarate, vital for Krebs cycle regulation,<xref ref-type="bibr" rid="bib19"><sup>19</sup></xref> was consistently increased in sera from patients with ACLF (n = 20) compared with controls (n = 11) and NIST (<xref ref-type="fig" rid="fig5">Figure 5</xref><italic toggle="yes">A</italic>) (<italic toggle="yes">P</italic> = .0002). Similarly, N-acetylglutamine, fundamental for nitrogen clearance,<xref ref-type="bibr" rid="bib25"><sup>25</sup></xref> was notably increased in sera from patients with ACLF (n = 13) compared with healthy controls (n = 8) and NIST (<xref ref-type="fig" rid="fig5">Figure 5</xref><italic toggle="yes">B</italic>) (<italic toggle="yes">P</italic> = .0153).<fig id="fig5" orientation="portrait" position="float"><label>Figure 5</label><caption><p><bold>Metabolomics analysis of ACLF patient sera: Frankfurt cohort.</bold> (<italic toggle="yes">A</italic>) <italic toggle="yes">Left</italic>: Concentration of α-ketoglutarate (ng/mL) across sample group’s sera (reference standard NIST, healthy controls, patients with ACLF). Median is represented in the center, minimum and maximum values at whiskers extremities. Statistical 1-way ANOVA analysis revealed significant difference among the means (∗<italic toggle="yes">P</italic> = .0002). <italic toggle="yes">Right</italic>: Fold change of α-ketoglutarate. Means and SDs are depicted. Control data points: n = 11; ACLF data points: n = 20. (<italic toggle="yes">B</italic>) <italic toggle="yes">Left</italic>: Concentration of N-acetylglutamine (ng/mL) across sample group’s sera (reference standard NIST, healthy controls, patients with ACLF). Median is represented in the center, minimum and maximum values at whiskers extremities. Statistical 1-way ANOVA analysis revealed significant difference among the means (∗<italic toggle="yes">P</italic> = .0153). <italic toggle="yes">Right</italic>: Fold change of N-acetylglutamine. Control data points: n = 8; ACLF data points: n = 13.</p></caption><graphic orientation="portrait" position="float" xlink:href="gr5.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></p></sec><sec id="sec1.5.2"><title>Bonn/Münster cohort</title><p id="p0080">Untargeted metabolomics of serum samples from acutely decompensated cirrhotic patients revealed elevated peak intensities of N8-acetylspermidine and indoleacetic acid across portal, hepatic, and cubital veins. Patients were stratified by MELD score (≤10 vs &gt;10) to assess disease severity. N8-acetylspermidine levels were significantly higher in patients with MELD &gt;10 (n = 19) compared with patients with MELD ≤10 (n = 13; <italic toggle="yes">P</italic> &lt; .01) (<xref ref-type="fig" rid="fig6">Figure 6</xref><italic toggle="yes">A</italic>), whereas indoleacetic acid levels were consistently lower in the MELD &gt;10 group across all compartments (<xref ref-type="fig" rid="fig6">Figure 6</xref><italic toggle="yes">B</italic>) (<italic toggle="yes">P</italic> &lt; .05). These findings suggest that N8-acetylspermidine accumulates with worsening liver function, potentially contributing to toxicity even at low concentrations, reflecting polyamine pathway dysregulation.<xref ref-type="bibr" rid="bib24"><sup>24</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib26"><sup>26</sup></xref> In contrast, indoleacetic acid inverse trend may indicate disrupted gut–liver microbial co-metabolism in advanced cirrhosis.<xref ref-type="bibr" rid="bib20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib27"><sup>27</sup></xref> Spearman correlations (biochemistry and disease scores) showed N8-acetylspermidine positively correlated with Child-Pugh category, MELD score, and the inflammatory marker C-reactive protein (CRP), linking it to disease severity and systemic inflammation. Indoleacetic acid negatively correlated with white blood cell count (WBCs), clotting ability (International Normalized Ratio [INR]), acute decompensation score (CLIF C AD), liver injury (aspartate aminotransaminase [AST]) and decompensation severity (Child-Pugh category), reinforcing its microbial origin and emphasizing the role of gut-liver interactions in acutely decompensated liver cirrhosis (<xref ref-type="fig" rid="fig6">Figure 6</xref><italic toggle="yes">C</italic>).<fig id="fig6" orientation="portrait" position="float"><label>Figure 6</label><caption><p><bold>Metabolomics analysis of ACLF patient sera: Bonn/Münster cohort.</bold> (<italic toggle="yes">A</italic>) Serum peak intensities in TIPS cohort patients of N8-acetylspermidine, grouped by different MELD score levels (for MELD &gt;10, n = 19; for MELD ≤10, n = 13), to determine differences across severity of the disease. Statistical significance was determined using 2-way ANOVA. ∗<italic toggle="yes">P</italic> &lt; .05; ∗∗<italic toggle="yes">P</italic> &lt; .01. (<italic toggle="yes">B</italic>) Serum peak intensities of indoleacetic acid in TIPS cohort patients, grouped by different MELD score levels, to determine differences across severity of the disease. Statistical significance was determined using 2-way ANOVA testing. (<italic toggle="yes">C</italic>) Spearman correlations of N8-acetylspermidine and indoleacetic acid with different disease markers in TIPS cohort patients. ∗<italic toggle="yes">P</italic> &lt; .05; ∗∗<italic toggle="yes">P</italic> &lt; .01.</p></caption><graphic orientation="portrait" position="float" xlink:href="gr6.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></p></sec></sec></sec><sec id="sec2"><title>Discussion</title><p id="p0085">The present study identifies distinct metabolites associated with gut bacterial infections and hepatotoxicity which may contribute to ACLF pathophysiology. Using an in vitro model of gut epithelial cell infection with <italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic> or <italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic> and subsequent metabolomics analysis, we uncovered species-specific metabolic signatures. Eight metabolites were selected for further analysis, all of which demonstrated toxic effects on HepG2 cells. Four, α-ketoglutarate, N-acetylglutamine, indoleacetic acid, and N8-acetylspermidine, were significantly elevated in sera from patients with AD and ACLF from 2 independent cohorts (Frankfurt and Bonn/Münster), potentially linking infection-induced metabolic shifts to ACLF.</p><p id="p0090">To uncover infection-associated metabolic alterations<xref ref-type="bibr" rid="bib9"><sup>9</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib10"><sup>10</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib17"><sup>17</sup></xref> and to mimic gut–liver crosstalk relevant to ACLF,<xref ref-type="bibr" rid="bib3">3</xref>, <xref ref-type="bibr" rid="bib4">4</xref>, <xref ref-type="bibr" rid="bib5">5</xref>, <xref ref-type="bibr" rid="bib6">6</xref> we performed metabolomic profiling on supernatants collected from Caco-2 cells infected with <italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic> or <italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic> (<xref ref-type="fig" rid="fig2">Figure 2</xref><italic toggle="yes">A</italic> and <italic toggle="yes">B</italic>), based on our rationale for strain selection (see Introduction). These analyses revealed specific metabolic changes associated to infections, from which we prioritized compounds previously linked to oxidative stress and ROS production (<xref ref-type="table" rid="tbl8">Table 8</xref>).<xref ref-type="bibr" rid="bib18">18</xref>, <xref ref-type="bibr" rid="bib19">19</xref>, <xref ref-type="bibr" rid="bib20">20</xref>, <xref ref-type="bibr" rid="bib21">21</xref>, <xref ref-type="bibr" rid="bib22">22</xref>, <xref ref-type="bibr" rid="bib23">23</xref>, <xref ref-type="bibr" rid="bib24">24</xref>, <xref ref-type="bibr" rid="bib25">25</xref>, <xref ref-type="bibr" rid="bib26">26</xref>, <xref ref-type="bibr" rid="bib27">27</xref>, <xref ref-type="bibr" rid="bib28">28</xref> In <italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic> infections, α-ketoglutarate, uridine, p-coumaric acid, and indoleacetic acid were prominent; in <italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic>, desthiobiotin, ß-pinene, N8-acetylspermidine, and N-acetylglutamine were identified (<xref ref-type="fig" rid="fig2">Figure 2</xref><italic toggle="yes">C–F</italic>). To assess their hepatotoxic potential, HepG2 cells were subsequently exposed to the infected intestinal supernatants harboring these compounds (<xref ref-type="fig" rid="fig3">Figure 3</xref>), individual metabolites, and compound mixtures (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Both approaches induced dose- and time-dependent reductions in HepG2 viability, suggesting synergistic toxicity and reflecting mechanisms relevant to liver cell damage. These results corroborate earlier studies, showing that high levels of these specific metabolites can display cytotoxicity. In fact, p-coumaric acid induces ROS-mediated mitochondrial dysfunction, leading to apoptosis in neural cells,<xref ref-type="bibr" rid="bib32"><sup>29</sup></xref> whereas indoleacetic acid exhibits broad toxicity across cell lines and animal models.<xref ref-type="bibr" rid="bib31"><sup>30</sup></xref> Excess of α-ketoglutarate promotes oxidative stress and destabilizes hypoxia-inducible factor 1-alpha (HIF-1α), impairing differentiation and inducing cell death in mesenchymal stromal precursors; in vivo, high doses cause diarrhea, weight loss, and anemia in Wistar rats.<xref ref-type="bibr" rid="bib28"><sup>28</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib29"><sup>31</sup></xref> N8-acetylspermidine also exhibits dose-dependent cytotoxicity when administered intraperitoneally in mice.<xref ref-type="bibr" rid="bib34"><sup>32</sup></xref><table-wrap id="tbl8" orientation="portrait" position="float"><label>Table 8</label><caption><p>Hepatotoxic Metabolites Identified In Vitro and Validated Ex Vivo</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Metabolites identified in vitro</th><th colspan="1" rowspan="1">Description</th><th colspan="1" rowspan="1">Metabolites validated ex vivo</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> infection experiments</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> α-ketoglutarate</td><td colspan="1" rowspan="1">Critical Krebs cycle intermediate, connected to mitochondrial dysfunction and oxidative stress,<xref ref-type="bibr" rid="bib10"><sup>10</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib19"><sup>19</sup></xref> potential nutrient source for bacteria,<xref ref-type="bibr" rid="bib19"><sup>19</sup></xref> toxic effects at higher concentrations<xref ref-type="bibr" rid="bib28"><sup>28</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib29"><sup>31</sup></xref></td><td colspan="1" rowspan="1">Yes<xref ref-type="table-fn" rid="tbl8fna">a</xref></td></tr><tr><td colspan="1" rowspan="1"> Indoleacetic acid</td><td colspan="1" rowspan="1">Product of tryptophan metabolism, implicates gut microbiota dysbiosis and gut-liver axis imbalance,<xref ref-type="bibr" rid="bib10"><sup>10</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib27"><sup>27</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib30"><sup>33</sup></xref> toxic effects at higher concentrations<xref ref-type="bibr" rid="bib31"><sup>30</sup></xref></td><td colspan="1" rowspan="1">Yes<xref ref-type="table-fn" rid="tbl8fnb">b</xref></td></tr><tr><td colspan="1" rowspan="1"> p-coumaric acid</td><td colspan="1" rowspan="1">Related to biosynthesis of aromatic amino acids, antioxidant and antitumor properties through modulation of cell cycle-related proteins and apoptosis-related proteins,<xref ref-type="bibr" rid="bib21"><sup>21</sup></xref> toxic effects at higher concentrations<xref ref-type="bibr" rid="bib32"><sup>29</sup></xref></td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1"> Uridine</td><td colspan="1" rowspan="1">Related to pyrimidine metabolism, involved in energy metabolism and redox balance,<xref ref-type="bibr" rid="bib18"><sup>18</sup></xref> potential nutrient source for bacteria<xref ref-type="bibr" rid="bib33"><sup>34</sup></xref></td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic> infection experiments</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> Desthiobiotin</td><td colspan="1" rowspan="1">Biotin precursor, vital role in synthesis of biotin coenzyme, crucial for various metabolic processes, mainly stored in liver<xref ref-type="bibr" rid="bib22"><sup>22</sup></xref></td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1"> N8-acetylspermidine</td><td colspan="1" rowspan="1">Derivate of polyamine pathway, disrupts cellular homeostasis by inducing oxidative stress, DNA damage, and activating apoptotic and autophagy pathways,<xref ref-type="bibr" rid="bib24"><sup>24</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib26"><sup>26</sup></xref> toxic effects at higher concentrations and pathogenicity contribution<xref ref-type="bibr" rid="bib34"><sup>32</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib35"><sup>35</sup></xref></td><td colspan="1" rowspan="1">Yes<xref ref-type="table-fn" rid="tbl8fnb">b</xref></td></tr><tr><td colspan="1" rowspan="1"> N-acetylglutamine</td><td colspan="1" rowspan="1">Allosteric activator of carbamoylphosphate synthetase I in urea cycle, reflects impairments in ammonia detoxification and nitrogen clearance, aligning with hyperammonemia<xref ref-type="bibr" rid="bib25"><sup>25</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib36"><sup>36</sup></xref></td><td colspan="1" rowspan="1">Yes<xref ref-type="table-fn" rid="tbl8fna">a</xref></td></tr><tr><td colspan="1" rowspan="1"> ß-pinene</td><td colspan="1" rowspan="1">Involved in terpenoids metabolic pathway<xref ref-type="bibr" rid="bib23"><sup>23</sup></xref></td><td colspan="1" rowspan="1">No</td></tr></tbody></table><table-wrap-foot><fn id="tbl8fna"><label>a</label><p id="ntpara0040">Validated in the Frankfurt cohort.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl8fnb"><label>b</label><p id="ntpara0045">Validated in the Bonn/Münster cohort.</p></fn></table-wrap-foot></table-wrap></p><p id="p0095">Beyond direct cytotoxicity, these compounds may additionally influence host–pathogen dynamics: indoleacetic acid, synthesized by various bacteria including <italic toggle="yes">Acinetobacter spp,</italic> enhances stress tolerance and biofilm formation, key to bacterial survival and pathogenicity.<xref ref-type="bibr" rid="bib30"><sup>33</sup></xref> N8-acetylspermidine modulates polyamine metabolism, aiding bacterial adaptation and immune evasion.<xref ref-type="bibr" rid="bib35"><sup>35</sup></xref> α-Ketoglutarate and uridine may serve as nutrient sources, supporting pathogen survival.<xref ref-type="bibr" rid="bib18"><sup>18</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib28"><sup>28</sup></xref> Collectively, the consistency of our findings across experimental setups reinforces the robustness of our conclusions, linking <italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic> and <italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic> infection-associated metabolites to alterations in liver cell function.<xref ref-type="bibr" rid="bib4"><sup>4</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib7"><sup>7</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib15"><sup>15</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib18"><sup>18</sup></xref></p><p id="p0100">The selection of this model, which involves infecting Caco-2 cells (intestinal epithelial cells) followed by the analysis of the effects induced by infection-associated metabolites on HepG2 cells (hepatocytes), is based on the observation that bacterial pathogens, particularly MDR strains under antibiotic pressure, initially colonize the intestine. The translocation of infection-associated hepatotoxic metabolites to the liver may represent the critical pathogenic mechanism underlying bacterially triggered ACLF in vivo. Notably, prior studies have demonstrated that bacterial infections can modulate the expression and localization of tight junction proteins in Caco-2 cells, leading to enhanced paracellular permeability and facilitating the translocation of bacteria or their metabolites across the epithelial barrier.<xref ref-type="bibr" rid="bib37">37</xref>, <xref ref-type="bibr" rid="bib38">38</xref>, <xref ref-type="bibr" rid="bib39">39</xref> It is therefore plausible to speculate that these bacteria, or their metabolites, might translocate from the intestinal microbiota to the liver via the portal vein, especially under conditions of gut barrier disruption. Furthermore, the in vitro experimental setup used, based on analyzing the bacterial metabolic signatures during their interaction with intestinal cells, lies at the intersection of intestinal cellular infection, gut lumen colonization, and dysbiosis, characterized by the overgrowth of specific bacterial species. In patients (eg, patients with ACLF), this results in direct contact between epithelial cells and the respective bacteria, potentially compromising gut barrier integrity (as discussed above) and thereby promoting the translocation of bacterial metabolites into the portal circulation through a “leaky” gut.<xref ref-type="bibr" rid="bib40"><sup>40</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib41"><sup>41</sup></xref> Our in vitro metabolomics analysis demonstrated that the selected metabolites are predominantly derived from the bacteria, with this effect even more pronounced under co-culture conditions (see <xref ref-type="table" rid="tbl2">Tables 2</xref> and <xref ref-type="table" rid="tbl3">3</xref>), suggesting that these compounds could be produced in vivo during intestinal overgrowth. This mechanism may be particularly relevant in ACLF, where increased intestinal permeability promotes the systemic dissemination of microbial products, contributing to the deterioration of liver function.<xref ref-type="bibr" rid="bib40"><sup>40</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib41"><sup>41</sup></xref> This process, potentially exacerbated by mitochondrial dysfunction and excessive ROS production in liver cells, may reflect metabolic imbalances possibly connected to ACLF<xref ref-type="bibr" rid="bib1"><sup>1</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib2"><sup>2</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib15"><sup>15</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib16"><sup>16</sup></xref> (<xref ref-type="fig" rid="fig7">Figure 7</xref>).<fig id="fig7" orientation="portrait" position="float"><label>Figure 7</label><caption><p><bold>Schematic representation of gut-liver axis imbalance as potential trigger of ACLF.</bold> Gut barrier impairment may facilitate the translocation of bacteria and microbial metabolites into the portal vein, thereby exacerbating hepatic injury. Within the liver, these translocated products, particularly those associated with bacterial infections, may contribute to mitochondrial oxidative stress, leading to excessive ROS production and metabolic dysregulation. This cascade of events could accelerate hepatocyte damage and contribute to the progression of ACLF (created in <ext-link ext-link-type="uri" id="intref0020" xlink:href="http://BioRender.com" xmlns:xlink="http://www.w3.org/1999/xlink">BioRender.com</ext-link> [<ext-link ext-link-type="uri" id="intref0025" xlink:href="https://biorender.com/pk055v4" xmlns:xlink="http://www.w3.org/1999/xlink">https://BioRender.com/pk055v4</ext-link>]).</p></caption><graphic orientation="portrait" position="float" xlink:href="gr7.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></p><p id="p0105">To translate in vitro experimental findings into clinical relevance across distinct patient populations and severity profiles, we applied metabolomics analysis on serum samples from 2 independent cohorts. In the Frankfurt cohort, derived from a prospective study, α-ketoglutarate (<xref ref-type="fig" rid="fig5">Figure 5</xref><italic toggle="yes">A</italic>; in <xref ref-type="table" rid="tbl8">Table 8</xref>) and N-acetylglutamine (<xref ref-type="fig" rid="fig5">Figure 5</xref><italic toggle="yes">B</italic>; in <xref ref-type="table" rid="tbl8">Table 8</xref>), were highly increased in sera from patients with ACLF of alcoholic origin compared with healthy controls. These metabolites are linked to TCA cycle dysregulation<xref ref-type="bibr" rid="bib10"><sup>10</sup></xref> and hyperammonemia-related nitrogen clearance disruptions,<xref ref-type="bibr" rid="bib36"><sup>36</sup></xref> respectively, both central mechanisms in ACLF. In the Bonn/Münster cohort, N8-acetylspermidine (<xref ref-type="fig" rid="fig6">Figure 6</xref><italic toggle="yes">A</italic>; <xref ref-type="table" rid="tbl8">Table 8</xref>) and indoleacetic acid (<xref ref-type="fig" rid="fig6">Figure 6</xref><italic toggle="yes">B</italic>; <xref ref-type="table" rid="tbl8">Table 8</xref>) were detected in sera from AD cirrhotic patients, stratified by MELD score to assess disease severity, exhibiting distinct trends. N8-acetylspermidine accumulates as liver function deteriorates, potentially exerting toxic effects even at lower concentrations.<xref ref-type="bibr" rid="bib24"><sup>24</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib26"><sup>26</sup></xref> In contrast, the indoleacetic acid shift may indicate disruptions in gut–liver microbial co-metabolism in advanced cirrhosis,<xref ref-type="bibr" rid="bib20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib27"><sup>27</sup></xref> altering metabolite production as decompensated cirrhosis advances. Both compounds have been previously associated with sepsis-related ACLF, reinforcing their relevance to infection-driven metabolic dysregulation.<xref ref-type="bibr" rid="bib10"><sup>10</sup></xref> It is important noting that the patients in our study had documented infections but did not meet criteria for sepsis, which would have been a contraindication for transjugular intrahepatic portosystemic shunt (TIPS), to prevent further clinical deterioration. Our data suggest that our metabolites panel, although released in vitro following infection with specific bacterial species (<italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic> or <italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic>), is generally detectable in vivo in patients with various bacterial infections, supporting a model of how infections impair liver function (see <xref ref-type="fig" rid="fig7">Figure 7</xref>).</p><p id="p0110">The partial overlap between the 8 candidate metabolites identified in vitro and those detected in patient sera (4 of which were significant) and the variation across cohorts reflects the complexity of human physiology. Although our in vitro model is well-suited to study localized bacteria-epithelial interactions along the gut-liver axis,<xref ref-type="bibr" rid="bib39"><sup>39</sup></xref> it does not capture the full range of systemic influences, such as hepatic dysregulation and immune modulation. In vivo, metabolites from bacterial colonization or infection may be rapidly altered, diluted, or masked by competing pathways, or amplified through inflammatory loops, depending on the host’s condition. This layered complexity might explain why some metabolites are detectable in vitro but not in patient blood, highlighting the need to integrate cellular models with clinical data to better understand infection-associated metabolic shifts.</p><p id="p0115">The divergence in metabolite profiles between the Frankfurt and Bonn/Münster cohorts further illustrates this point. In Frankfurt, elevated levels of α-ketoglutarate and N-acetylglutamine suggest mitochondrial dysfunction and impaired nitrogen metabolism, consistent with hepatic energy failure and urea cycle disruption.<xref ref-type="bibr" rid="bib10"><sup>10</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib36"><sup>36</sup></xref> In contrast, the Bonn/Münster cohort exhibited increased levels of N8-acetylspermidine and indoleacetic acid, linked to immune activation and microbiome-derived signaling, respectively.<xref ref-type="bibr" rid="bib20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib24"><sup>24</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib26"><sup>26</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib27"><sup>27</sup></xref> These distinct profiles reflect different biological axes (hepatic metabolic collapse vs gut-liver immune crosstalk), yet both contribute to systemic deterioration in ACLF. Importantly, these pathways may interact: inflammation can worsen mitochondrial stress, and nitrogen imbalance can amplify immune dysfunction. This dual-pathway perspective underscores the multifactorial nature of ACLF and supports the use of metabolomics to capture converging disease mechanisms.</p><p id="p0120">Our strategy bridges the mechanistic precision of in vitro infection models with the biological complexity of ex vivo patient data. Despite biological variability and systemic complexity of ACLF, 4 of 8 hepatotoxic metabolites were validated across both platforms, supporting their candidacy as potential biomarkers and therapeutic targets.<xref ref-type="bibr" rid="bib1"><sup>1</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib2"><sup>2</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib10">10</xref>, <xref ref-type="bibr" rid="bib11">11</xref>, <xref ref-type="bibr" rid="bib12">12</xref> These metabolites, derived from <italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic> or <italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic> infections, reflect conserved species-specific profiles that persist across reference, MDR, and highly virulent strains. This consistency suggests that species identity, rather than strain-level variation, shapes the metabolic landscape during infection. The clinical relevance of these metabolites originating from bacterial infections underscores the potential for targeted interventions in ACLF and personalized treatment strategies.</p></sec><sec id="sec3"><title>Materials and Methods</title><p id="p0125"><xref ref-type="table" rid="tbl9">Table 9</xref> compiles specifications of essential reagents and methodological parameters applied throughout the study.<table-wrap id="tbl9" orientation="portrait" position="float"><label>Table 9</label><caption><p>CTAT With Material Specifications</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="3" rowspan="1">Antibodies<hr/></th></tr><tr><th colspan="1" rowspan="1">Name</th><th colspan="1" rowspan="1">Supplier</th><th colspan="1" rowspan="1">Cat. No.</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Rabbit anti-<italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> IgG</td><td colspan="1" rowspan="1">Antigen produced by us; sera produced by Kaneka Eurogentec S.A.</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Rabbit anti-<italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic> IgG</td><td colspan="1" rowspan="1">Antigen produced by us; sera produced by Kaneka Eurogentec S.A.</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Alexa 488 conjugated anti-rabbit IgG</td><td colspan="1" rowspan="1">Dianova</td><td align="char" colspan="1" rowspan="1">154288</td></tr><tr><td colspan="1" rowspan="1">Alexa 647 conjugated anti-rabbit IgG</td><td colspan="1" rowspan="1">Dianova</td><td align="char" colspan="1" rowspan="1">151912</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th colspan="5" rowspan="1">Cell lines<hr/></th></tr><tr><th colspan="1" rowspan="1">Name</th><th colspan="1" rowspan="1">Supplier</th><th colspan="1" rowspan="1">Passage (p)</th><th colspan="1" rowspan="1">PCR mycoplasma</th><th colspan="1" rowspan="1">Authentication</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">HepG2</td><td colspan="1" rowspan="1">DSMZ, German Collection of Microorganisms and Cell Culture</td><td colspan="1" rowspan="1">p15-p16</td><td colspan="1" rowspan="1">Mycoplasma free</td><td colspan="1" rowspan="1">STR authentication</td></tr><tr><td colspan="1" rowspan="1">Caco-2</td><td colspan="1" rowspan="1">DSMZ, German Collection of Microorganisms and Cell Culture</td><td colspan="1" rowspan="1">p43-p44</td><td colspan="1" rowspan="1">Mycoplasma free</td><td colspan="1" rowspan="1">STR authentication</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th colspan="3" rowspan="1">Bacterial strains<hr/></th></tr><tr><th colspan="1" rowspan="1">Name</th><th colspan="1" rowspan="1">Supplier</th><th colspan="1" rowspan="1">Characteristics</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">AB 1: <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> 19606</td><td colspan="1" rowspan="1">ATCC, American Type Culture Collection</td><td colspan="1" rowspan="1">Reference strain</td></tr><tr><td colspan="1" rowspan="1">AB 2: <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> 1372</td><td colspan="1" rowspan="1">University Hospital Frankfurt am Main</td><td colspan="1" rowspan="1">Multidrug-resistant bacteria, patient isolate</td></tr><tr><td colspan="1" rowspan="1">AB 3: <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> 2778</td><td colspan="1" rowspan="1">University Hospital Frankfurt am Main</td><td colspan="1" rowspan="1">Multidrug-resistant bacteria and highly virulent, patient isolate</td></tr><tr><td colspan="1" rowspan="1">KP 1: <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic> 700603</td><td colspan="1" rowspan="1">ATCC, American Type Culture Collection</td><td colspan="1" rowspan="1">Reference strain</td></tr><tr><td colspan="1" rowspan="1">KP 2: <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic> 5989</td><td colspan="1" rowspan="1">University Hospital Frankfurt am Main</td><td colspan="1" rowspan="1">Multidrug-resistant bacteria, patient isolate</td></tr><tr><td colspan="1" rowspan="1">AB 3: <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic> 1664</td><td colspan="1" rowspan="1">University Hospital Frankfurt am Main</td><td colspan="1" rowspan="1">Multidrug-resistant bacteria and highly virulent, patient isolate</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th colspan="4" rowspan="1">Biological samples<hr/></th></tr><tr><th colspan="1" rowspan="1">Description</th><th colspan="1" rowspan="1">Source</th><th colspan="1" rowspan="1">Storage conditions</th><th colspan="1" rowspan="1">Ethics and approval</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Frankfurt cohort: sera from patients with ACLF and healthy patient sera</td><td colspan="1" rowspan="1">University Hospital Frankfurt am Main</td><td align="char" colspan="1" rowspan="1">−80°</td><td colspan="1" rowspan="1">Ref. 20-653 and 329-10, signed consent of all participants following the Declaration of Helsinki</td></tr><tr><td colspan="1" rowspan="1">Münster cohort: AD and sera from patients with ACLF</td><td colspan="1" rowspan="1">University Clinic Bonn</td><td align="char" colspan="1" rowspan="1">−80°</td><td colspan="1" rowspan="1">029/13 and 203/13, signed consent of all participants following the Declaration of Helsinki</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th colspan="3" rowspan="1">Metabolites<hr/></th></tr><tr><th colspan="1" rowspan="1">Name</th><th colspan="1" rowspan="1">Supplier</th><th colspan="1" rowspan="1">Source</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">α-ketoglutarate</td><td colspan="1" rowspan="1">Sigma-Aldrich</td><td colspan="1" rowspan="1">BCCH3270</td></tr><tr><td colspan="1" rowspan="1">Indoleacetic acid</td><td colspan="1" rowspan="1">Sigma-Aldrich</td><td colspan="1" rowspan="1">SLCL0192</td></tr><tr><td colspan="1" rowspan="1">p-coumaric acid</td><td colspan="1" rowspan="1">Sigma-Aldrich</td><td colspan="1" rowspan="1">BCCJ1325</td></tr><tr><td colspan="1" rowspan="1">Uridine</td><td colspan="1" rowspan="1">Sigma-Aldrich</td><td colspan="1" rowspan="1">BCCK4390</td></tr><tr><td colspan="1" rowspan="1">Desthiobiotin</td><td colspan="1" rowspan="1">Sigma-Aldrich</td><td colspan="1" rowspan="1">SLCP2674</td></tr><tr><td colspan="1" rowspan="1">N-acetylglutamine</td><td colspan="1" rowspan="1">Sigma-Aldrich</td><td colspan="1" rowspan="1">129K2577V</td></tr><tr><td colspan="1" rowspan="1">ß-pinene</td><td colspan="1" rowspan="1">Roth</td><td colspan="1" rowspan="1">7106.1</td></tr><tr><td colspan="1" rowspan="1">N8-acetylspermidine</td><td colspan="1" rowspan="1">Chemos</td><td colspan="1" rowspan="1">A0063942</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th colspan="3" rowspan="1">Software<hr/></th></tr><tr><th colspan="1" rowspan="1">Name</th><th colspan="1" rowspan="1">Manufacturer</th><th colspan="1" rowspan="1">Version</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Prism</td><td colspan="1" rowspan="1">GraphPad</td><td colspan="1" rowspan="1">8</td></tr><tr><td colspan="1" rowspan="1">Microsoft Office</td><td colspan="1" rowspan="1">Microsoft</td><td colspan="1" rowspan="1">2021</td></tr><tr><td colspan="1" rowspan="1">XCalibur</td><td colspan="1" rowspan="1">Thermo Fisher Scientific</td><td colspan="1" rowspan="1">4.4</td></tr><tr><td colspan="1" rowspan="1">TraceFinder</td><td colspan="1" rowspan="1">Thermo Fisher Scientific</td><td colspan="1" rowspan="1">5.1</td></tr><tr><td colspan="1" rowspan="1">Workflow4Metabolomics</td><td colspan="1" rowspan="1">MetaboHUB</td><td colspan="1" rowspan="1">3.0</td></tr><tr><td colspan="1" rowspan="1">Skyline</td><td colspan="1" rowspan="1">MacCoss, University of Washington</td><td colspan="1" rowspan="1">22.2.0.255</td></tr><tr><td colspan="1" rowspan="1">MatLab</td><td colspan="1" rowspan="1">MathWorks</td><td colspan="1" rowspan="1">2022b</td></tr></tbody></table><table-wrap-foot><fn><p>AB, <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic>; ACLF, acute-on-chronic liver failure; IgG, immunoglobulin G; KP, <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic>; PCR, polymerase chain reaction.</p></fn></table-wrap-foot></table-wrap></p><sec id="sec3.1"><title>Bacterial Strains and Cell Lines</title><p id="p0130">Infection experiments were performed using 6 strains of <italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic> and <italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic> (<xref ref-type="table" rid="tbl1">Table 1</xref>), including reference strains AB 1(<italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic> ATCC 19606<sup>T</sup>) and KP 1 (<italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic> ATCC 700603), purchased from DSMZ (German Collection of Microorganisms and Cell Culture). Bacteria were cultured on Columbia blood agar (CBA) plates (Thermo Fisher Scientific). The human immortalized HepG2 (hepatocarcinoma) and Caco-2 (adenocarcinoma) cell lines were acquired from DSMZ and cultivated in 75-cm<sup>2</sup> cell culture flasks using Dulbecco’s Modified Eagle Medium (DMEM;41965-039, Gibco) supplemented with 10% fetal calf serum (FCS; Sigma-Aldrich) without antibiotics. Culture flasks were incubated at 37°C in 5% CO<sub>2</sub> and 95% relative humidity. Passage numbers (p) were standardized across experiments: p15–p16 for HepG2 and p43–p44 for Caco-2 cells.</p></sec><sec id="sec3.2"><title>Infection of Caco-2 Cells With <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> or <italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic></title><p id="p0135">For infection experiments, Caco-2 cells were seeded into collagene-coated 24- or 96-well plates (Collagen G 0,4%, Matrix BioScience GmbH, diluted 1:40 in Dulbecco's phosphate-buffered saline no magnesium and no calcium (DPBS); Gibco) at a density of 5 × 10<sup>5</sup> or 80 × 10<sup>4</sup> cells/mL. Bacterial strains (<xref ref-type="table" rid="tbl1">Table 1</xref>) were cultured in lysogeny broth (LB; Becton Dickinson) at 37°C, starting from optical density at 600 nm (OD<sub>600</sub>) of 0.05 and grown to OD<sub>600</sub> of 0.2. Cultures were centrifuged (5000 × g for 15 minutes), washed with DPBS and resuspended in DMEM without antibiotics or FCS. Final multiplicity of infection (MOIs) was 100 for <italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic> and 1 for <italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic>. Cell culture plates were centrifuged for 3 minutes at 300 × g (to ensure bacterial contact to the surface of the cell layer) and incubated for 6 hours at 37°C, 5% CO<sub>2</sub> and relative humidity of 95%. Viable bacteria were quantified by serial dilutions on CBA plates (Thermo Fisher Scientific), with colony-forming units (CFU) counted after 24 hours at 37°C.</p></sec><sec id="sec3.3"><title>Generation of Anti-<italic toggle="yes">K</italic><italic toggle="yes">pneumoniae</italic> and <italic toggle="yes">A</italic><italic toggle="yes">baumannii</italic> Antibodies</title><p id="p0140">Rabbit anti-<italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic> immunoglobulin Gs (IgGs) were generated using a mix of 6 clinical isolates (derived from international clusters 1, 2, 4, 6, 7, 8<xref ref-type="bibr" rid="bib15"><sup>15</sup></xref>; including AB 2 from <xref ref-type="table" rid="tbl1">Table 1</xref>) and 2 reference strains (ATCC 17978, and AB 1: ATCC 19606<sup>T</sup> from <xref ref-type="table" rid="tbl1">Table 1</xref>). Rabbit anti-<italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic> IgGs were produced using 6 clinical isolates (including KP 2 and KP 3 from <xref ref-type="table" rid="tbl1">Table 1</xref>) and one reference strain (KP 1). Bacteria were cultured in LB broth (OD<sub>600</sub> = 0.7), washed 3 times with DPBS and inactivated with 10% formalin (VWR International GmbH) for 2 hours at 37°C. Two rabbits were immunized on days 0, 7, 10, and 18 with 5.75 × 10<sup>7</sup> inactivated bacteria per dose (Kaneka Eurogentec SA), and serum was collected on day 28. The reactivity of immune and pre-immune sera was evaluated by immunofluorescence at a dilution of 1:400 in DPBS.</p></sec><sec id="sec3.4"><title>Double Immunofluorescence Staining of Infected Caco-2 Cells</title><p id="p0145">Caco-2 cells were seeded on 12-mm coverslips (Karl/Hecht GmbH) in 24-well plates and afterwards infected for 6 hours with <italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic> (MOI 100) or <italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic> (MOI 1) in DMEM. Coverslips were washed 3 times with DPBS between staining steps. Cells were fixed using 3.75% paraformaldehyde (Sigma Aldrich; diluted in DBPS, pH 7.4) and blocked with 0.2% bovine serum albumin (BSA; Sigma-Aldrich) in DPBS for 15 minutes at room temperature (RT).</p><p id="p0150">Primary antibodies (1:200, rabbit-anti-<italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic>; 1:400, rabbit anti-<italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic>) and secondary antibodies (anti-rabbit Alexa Fluor 488 IgG, 1:200, Dianova), were applied for 1 hour at RT. Cells were then permeabilized with 0.2% Triton X-100 (AppliChem GmbH) for 15 minutes at RT and re-blocked. Intracellular bacteria were stained with the same primary antibodies and Alexa Fluor 647-conjiugated secondary antibody (anti-rabbit IgG, 1:200, Dianova). Tetramethylrhodamine (TRITC)-phalloidin (Sigma Aldrich) was used for actin cytoskeleton staining (1 hour, RT). DNA was stained with 4′,6-diamidino-2-phenylindole (DAPI; Merck) for 10 minutes. Coverslips were finally mounted on glass slides using Fluorescence Mounting Medium (Agilent Technologies). Fluorescence microscopy analysis was performed with the microscope Zeiss Axio Imager 2 (Zeiss) equipped with a Spot RT3 camera (Diagnostic Instruments Inc) and operated by VisiView V.2.0.5 (Visitron Systems). Images were aquired with 63× objective.</p></sec><sec id="sec3.5"><title>Untargeted Metabolomics for Semi-polar Metabolites Identification</title><p id="p0155">Two biological replicates per condition were generated from two independent experiments, each consisting of 3 replicates pooled at the supernatant level. Samples were collected from Caco-2 cells infected for 6 hours with <italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic> or <italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic>, alongside controls under identical conditions (uninfected Caco-2 cells and bacteria cultured without host cells) to ensure infection-specific effects. Samples were centrifuged at 4°C (20.817 × g for 10 minutes), filter-sterilized (0.22 μm pore size; Thermo Fisher Scientific), collected in low-binding tubes (Sorenson, BioScience), and stored at −80°C. Metabolomics were performed by cmbio. Samples (10 μL) were diluted in 100-μL eluent A (water, 10 mM ammonium formate, 0.1% formic acid) containing stable isotope-labeled metabolites. Analysis was conducted with ultra-high-performance liquid chromatography (UHPLC) Vanquish coupled to a Q Exactive HF Hybrid Quadrupole-Orbitrap (Thermo Fisher Scientific). Electrospray ionization was performed in positive and negative ionization mode under polarity switching. Data were processed using Compound Discoverer 3.3 (Thermo Fisher Scientific) and Skyline 22.2 (MacCoss Lab Software) for peak picking and feature grouping, followed by curation in MATLAB (2022b). Compound annotations followed 4 confidence levels (level 1: retention times [±0.2 minutes], accurate mass [± 3 ppm], and tandem mass spectrometry [MS/MS] spectra [match factor &gt;60] vs in-house standards; level 2a: retention times [±0.2 minutes], and accurate mass [±3 ppm] vs in-house standards; level 2b: accurate mass [±3 ppm], and MS/MS spectra vs in-house standards and mzCloud [Thermo Fisher Scientific] at a match factor &gt;60; level 3: identification by accurate mass alone [±3 ppm], based on the Human metabolome database [v 5.0]). Co-eluting isotopes with indistinguishable retention and fragmentation were manually integrated and reported as compound groups (eg, hexoses, sugar alcohols). This untargeted profiling approach enabled broad, transparent coverage of relative metabolite concentrations in supernatants.</p></sec><sec id="sec3.6"><title>Targeted Metabolomics for SCFA Identification</title><p id="p0160">SCFAs were quantified from 30 μL of cell culture supernatants samples (conditions described above), acidified using an aqueous solution of hydrochloric acid and deuterium-labelled internal standards (36 μL, 0.2 M HCl). Analysis was carried out on a high polarity column (Zebron ZB-FFAP, GC Cap. Column 30 m × 0.25 mm × 0.25 μm) installed in a gas chromatography (GC, 7890B, Agilent) coupled with a time-of-flight mass spectrometer (Pegasus BT, LECO). The system was controlled by ChromaTOF (LECO). Peak areas were integrated using Skyline (23.0, MacCoss Lab Software), before quantification against external calibration curves and curation (2022b, MathWorks). Matrix effects, carry over, noise levels, and precision were evaluated using corresponding quality control samples. This method specifically targets SCFAs, vital in maintaining the gut-liver axis balance by supporting gut barrier integrity and regulating metabolism.</p></sec><sec id="sec3.7"><title>Determination of Cell Viability Via XTT Assays</title><p id="p0165">For viability experiments, HepG2 cells were seeded into collagen-coated 96-well plates (40 × 10<sup>4</sup> cells/well), in FluoroBrite DMEM (Gibco), a phenol red-free medium to prevent nonspecific colorimetric interference, supplemented with 5% glutamine (GlutaMax, Gibco) and 10% FCS. Culture dishes were incubated overnight (5% CO<sub>2</sub>, 37°C, 95% relative humidity). Cell viability was assessed using sodium 3'-(1-(phenylaminocarbonyl)-3,4-tetrazolium)-bis(4-methoxy-6-nitro) benzene sulfonic acid hydrate (XTT) assay (Abcam). XTT reagent was added to each well and incubated for 2 hours. Subsequently, cell metabolic activity was monitored hourly over a 4-hour period. Kinetic reads of defined time points were performed at 450 to 620 nm using a microplate Sunrise-Basic reader (TECAN). This assay evaluates mitochondrial dehydrogenase activity via reduction of XTT (sodium 3'-(1-(phenylaminocarbonyl)-3,4-tetrazolium)-bis(4-methoxy-6-nitro) benzene sulfonic acid hydrate) to a water-soluble orange formazan. Formazan formation correlates with the number of metabolically active cells, driven by nicotinamide adenine dinucleotide phosphate, reduced form (NADH)-dependent electron transfer across the plasma membrane. The water-soluble formazan dissolves into the medium, allowing real-time kinetic measurements (according to the manufacturer’s instructions provided in the datasheet of the kit).<xref ref-type="bibr" rid="bib42"><sup>42</sup></xref> HepG2 viability was analyzed after exposure to 6-hour infected-Caco-2 conditioned medium or selected metabolites, with rigorous controls. Cell viability was calculated as follows:</p><p id="p0170"><inline-formula><mml:math altimg="si1.svg" id="M1" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi><mml:mspace width="0.25em"/><mml:mi>v</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>b</mml:mi><mml:mi>i</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>y</mml:mi><mml:mspace width="0.25em"/><mml:mo>%</mml:mo><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mfrac><mml:mrow><mml:mi>O</mml:mi><mml:mi>D</mml:mi><mml:mspace width="0.25em"/><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mspace width="0.25em"/><mml:mi>s</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mo>−</mml:mo><mml:mi>O</mml:mi><mml:mi>D</mml:mi><mml:mspace width="0.25em"/><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>O</mml:mi><mml:mi>D</mml:mi><mml:mspace width="0.25em"/><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mspace width="0.25em"/><mml:mi>s</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:mfrac><mml:mo>∗</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:math></inline-formula>.</p></sec><sec id="sec3.8"><title>Determination of HepG2 Cell Viability After Stimulation With Caco-2 Conditioned Medium</title><p id="p0175">To perform HepG2 cell viability after exposure to Caco-2 conditioned medium, Caco-2 cells were seeded in 24-well plate and infected with <italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic> or <italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic> strains for 6 hours. Conditioned media from uninfected Caco-2 cells and bacteria grown without host cells, incubated for 6 hours, served as rigorous control groups to ensure the robustness of the results. Supernatants were collected, centrifuged at 4°C (20.817 × g for 10 minutes), filter sterilized (0.22 μm) and stored at −80°C prior to use. Sterility was confirmed by incubating 100 μL of each supernatant on CBA plates for 24 hours. HepG2 cells, pre-seeded in a 96-well plate, were exposed to conditioned media at 5 different volumes, such as 100 μL, 50 μL, 25 μL, 10 μL, and 5 μL. Each well was supplemented with FluoroBrite DMEM (phenol red–free, FCS-free) to achieve a final volume of 100 μL. Exposure durations included 2 hours, 3 hours, and 4 hours. HepG2 cell viability was determined via XTT assay as described above.</p></sec><sec id="sec3.9"><title>Metabolite Preparation for Evaluating HepG2 Cell Viability After Exposure</title><p id="p0180">To assess HepG2 cell viability after exposure to selected metabolites identified previously via metabolomics of Caco-2 infection supernatants and controls (uninfected Caco-2 and bacteria-only cultures), the following compounds were tested: α-ketoglutarate, indole-3 acetic acid, p-coumaric acid, uridine, desthiobiotin, N-acetylglutamine (all Sigma-Aldrich); ß-pinene (Roth); and N8-acetylspermidine (Chemos). Stock solutions were freshly prepared in DMSO (Roth), at the following concentrations: α-ketoglutarate, uridine: 10 mg/mL; indole-3 acetic acid, p-coumaric acid: 15 mg/mL; desthiobiotin, ß-pinene: 20 mg/mL; N8-acetylspermidine, N-acetylglutamine: 30 mg/mL. Stocks were diluted in FluoroBrite DMEM (phenol red–free, FCS-free) to final concentrations of 50, 100, 250, and 500 μg/mL. HepG2 cells were exposed for 2, 3, and 4 hours, and viability was measured via XTT assay. Two compound mixtures were also tested at identical concentrations and time points: (1) α-ketoglutarate, indole-3 acetic acid, p-coumaric acid, uridine (from <italic toggle="yes">A</italic>
<italic toggle="yes">baumannii</italic> experiments); and (2) desthiobiotin, ß-pinene, N8-acetylspermidine, N-acetylglutamine (from <italic toggle="yes">K</italic>
<italic toggle="yes">pneumoniae</italic> experiments), each containing equal amounts of the respective metabolites. DMSO-only controls matched solvent concentrations to ensure that observed effects on HepG2 cells were metabolite-specific.</p></sec><sec id="sec3.10"><title>Patients and Healthy Volunteers</title><sec id="sec3.10.1"><title>Frankfurt cohort</title><p id="p0185">To validate in vitro findings, clinically unannotated serum samples from patients with ACLF were retrospectively analyzed within the ongoing prospective longitudinal study “Characterization and Pathogenesis of ACLF” (ACLF-I, <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT04975490" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04975490</ext-link>). Adult patients with liver cirrhosis admitted to the Department of Internal Medicine 1 at University Hospital Frankfurt between 2021 and 2024 were enrolled. Cirrhosis was diagnosed based on liver biopsy or a combination of clinical, laboratory, imaging, and endoscopic findings. ACLF was defined according to CANONIC study criteria,<xref ref-type="bibr" rid="bib1"><sup>1</sup></xref> and organ failure assessed using the CLIF-C OF score.<xref ref-type="bibr" rid="bib43"><sup>43</sup></xref> For metabolomics, a subgroup of patients with ACLF with alcohol-related liver cirrhosis (N = 20) was selected. Alcohol-related etiology was defined by a reported daily alcohol intake exceeding 20 g/day. Healthy controls (N = 11) were included using samples obtained from the DRK Blood Donation Service Baden-Württemberg/Hessen (<xref ref-type="table" rid="tbl6">Table 6</xref>). Ethical approval was granted by the Institutional Ethics Committee of University Hospital Frankfurt (Ref. 20-653 and 329-10), and written informed consent was obtained from all participants in accordance with the Declaration of Helsinki.</p></sec><sec id="sec3.10.2"><title>Bonn/Münster cohort</title><p id="p0190">Serum samples from 32 patients with acutely decompensated liver cirrhosis as part of the NEPTUN study (<ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03628807" xmlns:xlink="http://www.w3.org/1999/xlink">NCT03628807</ext-link>) collected between 2014 and 2018 at the Department of Internal Medicine I, University Clinic Bonn (Germany) were used for validation. During TIPS insertion, blood samples were collected from the portal (PV), hepatic (LV), and cubital veins (CV) of all patients for laboratory serum and metabolic profiling. Disease severity in these patients was assessed by MELD score,<xref ref-type="bibr" rid="bib44"><sup>44</sup></xref> Child-Pugh score, CLIF acute decompensation (CLIF C AD) and ACLF (CLIF C ACLF) scores,<xref ref-type="bibr" rid="bib43"><sup>43</sup></xref> respectively (<xref ref-type="table" rid="tbl7">Table 7</xref>). The study was approved by the local ethics committee of the University of Bonn (029/13 and 203/13), and all patients signed an informed written consent following the Helsinki Declaration.<xref ref-type="bibr" rid="bib45"><sup>45</sup></xref></p></sec></sec><sec id="sec3.11"><title>Blood Sampling and Data Collection</title><p id="p0195">Clinical data, laboratory data, and serum samples were obtained at baseline. Routine laboratory diagnostics included liver function tests, differential WBC count, CRP, AST, alanine transaminase (ALT), INR, drinking and smoking behavior, gastrointestinal bleeding, ascites, therapeutic paracentesis, albumin treatments, diabetes and diabetes treatment, TIPS, hepatitis/viral infections, renal failure, respiratory failure, circulatory failure, and data on bacterial and/or fungal infection development.</p></sec><sec id="sec3.12"><title>Processing of Blood Samples and Serum Isolation</title><p id="p0200">Serum samples (9 mL) from patients with ACLF and healthy controls centrifuged at 1400 × g for 10 min at 4°C. The supernatant (serum) was aliquoted and stored at −80°C until further use.</p></sec><sec id="sec3.13"><title>Metabolomics Analysis of Patient Sera</title><sec id="sec3.13.1"><title>Frankfurt cohort</title><p id="p0205">Metabolite analysis was performed using liquid chromatography-high resolution mass spectrometry (LC-HRMS). Briefly, 10 μL of serum was mixed with 20 μL of methanol, 10 μL of 800 ng/mL uridine-13C5 in methanol and 70 μL of acetonitrile, then incubated at −20°C for 2 hours. After centrifugation (4°C at 18.000 × g for 10 minutes), 80 μL of the supernatant was evaporated under nitrogen at 45°C and reconstituted in 80 μL of 50% acetonitrile. Samples were randomized and included pooled serum from 10 random samples and human ethylene diamine tetra-acetic acid (EDTA) plasma replicates as quality controls. Reference standards SRM 1950 NIST (Thermo Fisher Scientific) were diluted in methanol and extracted similar to the samples with 10 μL of DPBS instead of serum, and 20 μL of the respective standard solution instead of methanol. LC-HRMS was performed on an Orbitrap Exploris 480 with a Vanquish Horizon UHPLC system (both Thermo Fisher Scientific), operating both in positive and negative ion mode. The separation was achieved using a SeQuant ZIC-HILIC column (3.5 μm, 100 mm × 2.1 mm I.D., Merck) with a same type of guard column and an inline filter. Data were acquired using XCalibur v4.4 software and evaluated using TraceFinder software v5.1 (both Thermo Fisher Scientific).</p></sec><sec id="sec3.13.2"><title>Bonn/Münster cohort</title><p id="p0210">Metabolite extraction was performed twice for further LC/HRMS analyses with 2 chromatographic columns (ie, HILIC and C18) from 50 μL of plasma using methanol-assisted protein precipitation, as previously described.<xref ref-type="bibr" rid="bib46"><sup>46</sup></xref> Briefly, a volume of 200 μL of methanol containing internal standards at 3.75 μg/mL (dimetridazole, 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl) propanoic acid [AMPA], 2-methyl-4-chlorophenoxyacetic acid [MCPA], and Dinoseb [Sigma-Aldrich]) was added to the 50 μL of plasma. The resulting samples were then left on ice for 90 minutes until complete protein precipitation. After a centrifugation step at 20,000 g for 15 minutes at 4°C, supernatants were collected and dried under a nitrogen stream using a TurboVap instrument (Thermo Fisher Scientific) and stored at −80°C until analysis. Prior to LC-MS analysis, dried extracts were resuspended in 150 μL of ammonium carbonate 10 mM pH10.5 + external standards solution (ESS∗)/Acetonitrile (40:60, v/v) for ZIC-pHILIC analysis or H2O/Acetonitrile (95:5, v/v), containing 0.1% formic acid and ESS∗ for C18 analysis. After reconstitution, the tubes were vortexed and incubated in an ultrasonic bath for 5 minutes and then centrifuged at 20,000 g for 15 minutes at 4°C. Supernatant was transferred into 0.2 mL vials. A quality control (QC) sample was obtained by pooling 20 μL of each sample preparation. QC samples were injected every 10 samples to evaluate the signal variations of any metabolite.</p><p id="p0215">ESS∗, a mixture of 9 authentic chemical standards covering the mass range of interest (13C-glucose, 15N-aspartate, ethylmalonic acid, amiloride, prednisone, metformin, atropine sulfate, colchicine, imipramine) was added to all samples to check the consistency of analytical results in terms of signal and retention time stability during the experiments.</p><p id="p0220">Untargeted metabolomics experiments were performed by LC-HRMS, using a combination of 2 complementary chromatographic methods<xref ref-type="bibr" rid="bib46"><sup>46</sup></xref> consisting of reversed-phase chromatography (C18 chromatographic column) and hydrophilic interaction chromatography (HILIC) for the analysis of hydrophobic and polar metabolites, respectively. LC-HRMS experiments were performed by using an Ultimate 3000 chromatographic system (Thermo Fisher Scientific) coupled to an Exactive mass spectrometer from Thermo Fisher Scientific fitted with an electrospray (ESI) source and operating in the positive and negative ion modes for metabolite separations on C18 and HILIC columns (see below), respectively. Chromatographic conditions were exactly those previously described by our group,<xref ref-type="bibr" rid="bib46"><sup>46</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib47"><sup>47</sup></xref> whereas the mass spectrometer was operated with capillary voltage at −3 kV in the negative ionization mode and 3 kV in the positive ionization mode and the capillary temperature set at 280°C. The sheath gas pressure and the auxiliary gas pressure were set at 60 and 20 arbitrary units with nitrogen gas, respectively. The detection was achieved from m/z 70 to 1000 at 50,000 resolution in both ionization modes. Data acquisition was performed in a single batch, in a randomized order, with quality control samples injected regularly. Data processing analyses were performed using the Workflow4Metabolomics (W4M) platform.<xref ref-type="bibr" rid="bib47"><sup>47</sup></xref> Metabolite features were first annotated according to accurate measured masses and chromatographic retention times by using our spectral database<xref ref-type="bibr" rid="bib47"><sup>47</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib48"><sup>48</sup></xref> and filtered by peak correlation, repeatability, and biological-to-blank peak ratios. Metabolite identification was further confirmed using MS/MS data collected under non-resonant collision-induced dissociation conditions using higher-energy C-trap dissociation (HCD) using a Q-Exactive mass spectrometer from Thermo Fisher Scientific. MS/MS data were further matched both manually using Xcalibur constructor software (Thermo Fisher Scientific) and automatically using the MS-DIAL software to the spectra included in our in-house spectral database, as previously described.<xref ref-type="bibr" rid="bib48"><sup>48</sup></xref> To be identified, metabolites had to match at least 2 orthogonal criteria (ie, accurate measured mass, retention time, MS/MS spectrum) to those of an authentic chemical standard analyzed under the same analytical conditions, as proposed by the Metabolomics Standards Initiative.<xref ref-type="bibr" rid="bib46"><sup>46</sup></xref></p></sec></sec><sec id="sec3.14"><title>Statistics and Data Analysis</title><p id="p0225">All experiments were performed in triplicates, at least 3 times, independently. Values are means ± standard deviation (SD). Statistical analyses included χ<sup>2</sup> (for comparison of categorical variables), 1-way analysis of variance (ANOVA) (to assess effect of a single independent variable) and a 2-way ANOVA (to evaluate effects of 2 independent variables), using GraphPad Prism V8 (GraphPad). A value of <italic toggle="yes">P</italic> &lt; .05 was considered statistically significant. For immunofluorescence and microscopy, representative pictures from at least 25 high-power fields are depicted.</p></sec><sec id="sec3.15"><title>Ethics</title><p id="p0230">This study was approved by the Institutional Ethics Committee University Hospital Frankfurt am Main (Germany) with reference number 20-653 for ACLF-I cohort patients’ sera, and reference number 329-10 for the DRK Blood Donation Service Baden-Württemberg/Hessen (Frankfurt am Main, Germany) patients’ sera. The blood collection and analysis in the validation cohort were approved by the local ethics committee of the University of Bonn (029/13 and 203/13). Written consent was obtained from all participants in accordance with the Declaration of Helsinki.</p></sec></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation id="sref1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreau</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jalan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gines</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis</article-title><source>Gastroenterology</source><volume>144</volume><year>2013</year><fpage>1426</fpage><lpage>1437.e1–9</lpage><pub-id pub-id-type="pmid">23474284</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1053/j.gastro.2013.02.042</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation id="sref2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trebicka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Papp</surname><given-names>M.</given-names></name><etal/></person-group><article-title>PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis</article-title><source>J Hepatol</source><volume>74</volume><year>2021</year><fpage>1097</fpage><lpage>1108</lpage><pub-id pub-id-type="pmid">33227350</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhep.2020.11.019</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation id="sref3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milosevic</surname><given-names>I.</given-names></name><name name-style="western"><surname>Vujovic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barac</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature</article-title><source>Int J Mol Sci</source><volume>20</volume><year>2019</year><fpage>395</fpage><pub-id pub-id-type="pmid">30658519</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.3390/ijms20020395</pub-id><pub-id pub-id-type="pmcid">PMC6358912</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation id="sref4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trebicka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reiberger</surname><given-names>T.</given-names></name><name name-style="western"><surname>Laleman</surname><given-names>W.</given-names></name></person-group><article-title>Gut-liver axis links portal hypertension to acute-on-chronic liver failure</article-title><source>Visc Med</source><volume>34</volume><year>2018</year><fpage>270</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">30345284</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1159/000490262</pub-id><pub-id pub-id-type="pmcid">PMC6189544</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation id="sref5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name></person-group><article-title>Gut–liver axis as a therapeutic target for drug-induced liver injury</article-title><source>Curr Issues Mol Biol</source><volume>46</volume><year>2024</year><fpage>1219</fpage><lpage>1236</lpage><pub-id pub-id-type="pmid">38392196</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.3390/cimb46020078</pub-id><pub-id pub-id-type="pmcid">PMC10887627</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation id="sref6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stecher</surname><given-names>B.</given-names></name><name name-style="western"><surname>Maier</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hardt</surname><given-names>W.D.</given-names></name></person-group><article-title>'Blooming' in the gut: how dysbiosis might contribute to pathogen evolution</article-title><source>Nat Rev Microbiol</source><volume>11</volume><year>2013</year><fpage>277</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">23474681</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/nrmicro2989</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation id="sref7" publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance</source><year>2024</year><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc></element-citation></ref><ref id="bib8"><label>8</label><element-citation id="sref8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bray</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Zafar</surname><given-names>M.A.</given-names></name></person-group><article-title>Deciphering the gastrointestinal carriage of <italic toggle="yes">Klebsiella pneumoniae</italic></article-title><source>Infect Immun</source><volume>92</volume><year>2024</year><object-id pub-id-type="publisher-id">e0048223</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1128/iai.00482-23</pub-id><pub-id pub-id-type="pmcid">PMC11384780</pub-id><pub-id pub-id-type="pmid">38597634</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation id="sref9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferstl</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Filmann</surname><given-names>N.</given-names></name><name name-style="western"><surname>Heilgenthal</surname><given-names>E.M.</given-names></name><etal/></person-group><article-title>Colonization with multidrug-resistant organisms is associated with increased mortality in liver transplant candidates</article-title><source>PLoS One</source><volume>16</volume><year>2021</year><object-id pub-id-type="publisher-id">e0245091</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1371/journal.pone.0245091</pub-id><pub-id pub-id-type="pmcid">PMC7822319</pub-id><pub-id pub-id-type="pmid">33481811</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation id="sref10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreau</surname><given-names>R.</given-names></name><name name-style="western"><surname>Clària</surname><given-names>J.</given-names></name><name name-style="western"><surname>Aguilar</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF</article-title><source>J Hepatol</source><volume>72</volume><year>2020</year><fpage>688</fpage><lpage>701</lpage><pub-id pub-id-type="pmid">31778751</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhep.2019.11.009</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation id="sref11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schierwagen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Brieger</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Pathogenetic mechanisms and therapeutic approaches of acute-to-chronic liver failure</article-title><source>Am J Physiol Cell Physiol</source><volume>325</volume><year>2023</year><fpage>C129</fpage><lpage>C140</lpage><pub-id pub-id-type="pmid">37273239</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1152/ajpcell.00101.2023</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation id="sref12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Metabolic dysregulation and metabolite imbalances in acute-on-chronic liver failure: impact on immune status</article-title><source>J Clin Transl Hepatol</source><volume>12</volume><year>2024</year><fpage>865</fpage><lpage>877</lpage><pub-id pub-id-type="pmid">39440217</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.14218/JCTH.2024.00203</pub-id><pub-id pub-id-type="pmcid">PMC11491507</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation id="sref13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaub</surname><given-names>I.G.</given-names></name><name name-style="western"><surname>Hauber</surname><given-names>F.D.</given-names></name></person-group><article-title>A biochemical and serological study of a group of identical unidentifiable gram-negative bacilli from human sources</article-title><source>J Bacteriol</source><volume>56</volume><year>1948</year><fpage>379</fpage><lpage>385</lpage><pub-id pub-id-type="pmid">16561584</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1128/jb.56.4.379-385.1948</pub-id><pub-id pub-id-type="pmcid">PMC518597</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation id="sref14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rasheed</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Yigit</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Characterization of the extended-spectrum beta-lactamase reference strain, <italic toggle="yes">Klebsiella pneumoniae</italic> K6 (ATCC 700603), which produces the novel enzyme SHV-18</article-title><source>Antimicrob Agents Chemother</source><volume>44</volume><year>2000</year><fpage>2382</fpage><lpage>2388</lpage><pub-id pub-id-type="pmid">10952583</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1128/aac.44.9.2382-2388.2000</pub-id><pub-id pub-id-type="pmcid">PMC90073</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation id="sref15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leukert</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tietgen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Krause</surname><given-names>F.F.</given-names></name><etal/></person-group><article-title>Infection of endothelial cells with <italic toggle="yes">Acinetobacter baumannii</italic> reveals remodelling of mitochondrial protein complexes</article-title><source>Microbiol Spectr</source><volume>11</volume><year>2023</year><object-id pub-id-type="publisher-id">e0517422</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1128/spectrum.05174-22</pub-id><pub-id pub-id-type="pmcid">PMC10269660</pub-id><pub-id pub-id-type="pmid">37052493</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation id="sref16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamprecht</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sommer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Willmann</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Pathogenicity of clinical OXA-48 isolates and impact of the OXA-48 IncL plasmid on virulence and bacterial fitness</article-title><source>Front Microbiol</source><volume>10</volume><year>2019</year><fpage>2509</fpage><pub-id pub-id-type="pmid">31736929</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.3389/fmicb.2019.02509</pub-id><pub-id pub-id-type="pmcid">PMC6838017</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation id="sref17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mücke</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Rumyantseva</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mücke</surname><given-names>V.T.</given-names></name><etal/></person-group><article-title>Bacterial infection-triggered acute-on-chronic liver failure is associated with increased mortality</article-title><source>Liver Int</source><volume>38</volume><year>2018</year><fpage>645</fpage><lpage>653</lpage><pub-id pub-id-type="pmid">28853199</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/liv.13568</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation id="sref18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belosludtseva</surname><given-names>N.V.</given-names></name><name name-style="western"><surname>Pavlik</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Mikheeva</surname><given-names>I.B.</given-names></name><name name-style="western"><surname>Belosludtsev</surname><given-names>K.N.</given-names></name></person-group><article-title>Protective effect of uridine on structural and functional rearrangements in heart mitochondria after a high-dose isoprenaline exposure modelling stress-induced cardiomyopathy in rats</article-title><source>Int J Mol Sci</source><volume>24</volume><year>2023</year><object-id pub-id-type="publisher-id">17300</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.3390/ijms242417300</pub-id><pub-id pub-id-type="pmcid">PMC10744270</pub-id><pub-id pub-id-type="pmid">38139129</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation id="sref19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>You</surname><given-names>J.S.</given-names></name></person-group><article-title>αKG-induced oxidative stress and mTOR inhibition as a therapeutic strategy for liver cancer</article-title><source>Med Oncol</source><volume>42</volume><year>2025</year><fpage>105</fpage><pub-id pub-id-type="pmid">40080333</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s12032-025-02653-0</pub-id><pub-id pub-id-type="pmcid">PMC11906577</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation id="sref20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Biosynthetic pathways and functions of indole-3-acetic acid in microorganisms</article-title><source>Microorganisms</source><volume>11</volume><year>2023</year><fpage>2077</fpage><pub-id pub-id-type="pmid">37630637</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.3390/microorganisms11082077</pub-id><pub-id pub-id-type="pmcid">PMC10459833</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation id="sref21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Posadino</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Cossu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Giordo</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Coumaric acid induces mitochondrial damage and oxidative-mediated cell death of human endothelial cells</article-title><source>Cardiovasc Toxicol</source><volume>13</volume><year>2013</year><fpage>301</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">23504614</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s12012-013-9205-3</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation id="sref22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sghaier</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zarrouk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nury</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Biotin attenuation of oxidative stress, mitochondrial dysfunction, lipid metabolism alteration, and 7β-hydroxycholesterol-induced cell death in 158N murine oligodendrocytes</article-title><source>Free Radic Res</source><volume>53</volume><year>2019</year><fpage>535</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">31039616</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1080/10715762.2019.1612891</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation id="sref23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dahiya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>M.</given-names></name></person-group><article-title>Ameliorative effect of β-pinene targeting mitochondrial dysfunction and oxidative stress in Alzheimer’s disease</article-title><source>Alzheimers Dement</source><volume>19</volume><year>2023</year><object-id pub-id-type="publisher-id">e076020</object-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation id="sref24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abela</surname><given-names>L.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>L.</given-names></name><name name-style="western"><surname>Steindl</surname><given-names>K.</given-names></name><etal/></person-group><article-title>N8-acetylspermidine as a potential plasma biomarker for Snyder-Robinson syndrome identified by clinical metabolomics</article-title><source>J Inherit Metab Dis</source><volume>39</volume><year>2016</year><fpage>131</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">26174906</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s10545-015-9876-y</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation id="sref25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ah Mew</surname><given-names>N.</given-names></name><name name-style="western"><surname>Caldovic</surname><given-names>L.</given-names></name></person-group><article-title>N-acetylglutamate synthase deficiency: an insight into the genetics, epidemiology, pathophysiology, and treatment</article-title><source>Appl Clin Genet</source><volume>4</volume><year>2011</year><fpage>127</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">23776373</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.2147/TACG.S12702</pub-id><pub-id pub-id-type="pmcid">PMC3681184</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation id="sref26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shangguan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Spermidine regulates mitochondrial function by enhancing eIF5A hypusination and contributes to reactive oxygen species production and ganoderic acid biosynthesis in <italic toggle="yes">Ganoderma lucidum</italic></article-title><source>Appl Environ Microbiol</source><volume>88</volume><year>2022</year><object-id pub-id-type="publisher-id">e0203721</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1128/aem.02037-21</pub-id><pub-id pub-id-type="pmcid">PMC8939328</pub-id><pub-id pub-id-type="pmid">35108082</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation id="sref27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>H.T.H.</given-names></name><name name-style="western"><surname>Umemura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kawano</surname><given-names>T.</given-names></name></person-group><article-title>Indole-3-acetic acid-induced oxidative burst and an increase in cytosolic calcium ion concentration in rice suspension culture</article-title><source>Biosci Biotechnol Biochem</source><volume>80</volume><year>2016</year><fpage>1546</fpage><lpage>1554</lpage><pub-id pub-id-type="pmid">27149194</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1080/09168451.2016.1179094</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation id="sref28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Krug</surname><given-names>L.</given-names></name><name name-style="western"><surname>Basu</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Alpha-ketoglutarate curbs differentiation and induces cell death in mesenchymal stromal precursors with mitochondrial dysfunction</article-title><source>Stem Cells</source><volume>35</volume><year>2017</year><fpage>1704</fpage><lpage>1718</lpage><pub-id pub-id-type="pmid">28398002</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/stem.2629</pub-id></element-citation></ref><ref id="bib32"><label>29</label><element-citation id="sref32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shailasree</surname><given-names>S.</given-names></name><name name-style="western"><surname>Venkataramana</surname><given-names>M.</given-names></name><name name-style="western"><surname>Niranjana</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Prakash</surname><given-names>H.S.</given-names></name></person-group><article-title>Cytotoxic effect of p-coumaric acid on neuroblastoma N2a cells via generation of reactive oxygen species leading to dysfunction of mitochondria inducing apoptosis and autophagy</article-title><source>Mol Neurobiol</source><volume>51</volume><year>2015</year><fpage>119</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">24760364</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s12035-014-8700-2</pub-id></element-citation></ref><ref id="bib31"><label>30</label><element-citation id="sref31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ismail</surname><given-names>H.T.H.</given-names></name><name name-style="western"><surname>Tarek</surname><given-names>H.</given-names></name></person-group><article-title>Assessment of toxic effects of exposure to 3-indoleacetic acid via hemato-biochemical, hormonal, and histopathological screening in rats</article-title><source>Environ Sci Pollut Res Int</source><volume>29</volume><year>2022</year><fpage>90703</fpage><lpage>90718</lpage><pub-id pub-id-type="pmid">35876993</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s11356-022-22026-8</pub-id><pub-id pub-id-type="pmcid">PMC9722852</pub-id></element-citation></ref><ref id="bib29"><label>31</label><element-citation id="sref29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhattacharya</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gujar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Toxicity of alpha-ketoglutarate following 14-days repeated oral administration in Wistar rats</article-title><source>Cell Mol Biol</source><volume>57</volume><issue>Suppl</issue><year>2011</year><fpage>OL1543</fpage><lpage>OL1549</lpage><pub-id pub-id-type="pmid">21791173</pub-id></element-citation></ref><ref id="bib34"><label>32</label><element-citation id="sref34" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Alshabanah</surname><given-names>O.A.</given-names></name></person-group><part-title>Toxicology and pharmacology of N<sup>1</sup>-acetylspermidine and N<sup>8</sup>-acetylspermidine [dissertation]</part-title><year>1981</year><publisher-name>University of the Pacific</publisher-name><publisher-loc>Stockton, CA</publisher-loc></element-citation></ref><ref id="bib30"><label>33</label><element-citation id="sref30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bianco</surname><given-names>C.</given-names></name><name name-style="western"><surname>Imperlini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Calogero</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Indole-3-acetic acid improves <italic toggle="yes">Escherichia coli</italic>’s defenses to stress</article-title><source>Arch Microbiol</source><volume>185</volume><year>2006</year><fpage>373</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">16555073</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s00203-006-0103-y</pub-id></element-citation></ref><ref id="bib33"><label>34</label><element-citation id="sref33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Improvement of uridine production in <italic toggle="yes">Bacillus subtilis</italic> by metabolic engineering</article-title><source>Biotechnol Lett</source><volume>40</volume><year>2018</year><fpage>151</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">29038923</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s10529-017-2453-8</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation id="sref35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaiser</surname><given-names>A.</given-names></name></person-group><article-title>The role of spermidine and its key metabolites in important, pathogenic human viruses and in parasitic infections caused by <italic toggle="yes">Plasmodium falciparum</italic> and <italic toggle="yes">Trypanosoma brucei</italic></article-title><source>Biomolecules</source><volume>13</volume><year>2023</year><fpage>803</fpage><pub-id pub-id-type="pmid">37238673</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.3390/biom13050803</pub-id><pub-id pub-id-type="pmcid">PMC10216422</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation id="sref36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dawkins</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Case report: management of intracranial hypertension in acute-on-chronic liver failure: a case of fulminant cerebral edema and acute-onset severe hyperammonemia in a patient with cirrhosis</article-title><source>Front Gastroenterol</source><volume>4</volume><year>2025</year><object-id pub-id-type="publisher-id">1542588</object-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation id="sref37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title><italic toggle="yes">Acinetobacter baumannii</italic> outer membrane protein A induces pulmonary epithelial barrier dysfunction and bacterial translocation through the TLR2/IQGAP1 axis</article-title><source>Front Immunol</source><volume>13</volume><year>2022</year><object-id pub-id-type="publisher-id">927955</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.3389/fimmu.2022.927955</pub-id><pub-id pub-id-type="pmcid">PMC9280087</pub-id><pub-id pub-id-type="pmid">35844614</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation id="sref38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.Y.</given-names></name><etal/></person-group><article-title><italic toggle="yes">Klebsiella pneumoniae</italic> translocates across the intestinal epithelium via Rho GTPase- and phosphatidylinositol 3-kinase/Akt-dependent cell invasion</article-title><source>Infect Immun</source><volume>83</volume><year>2015</year><fpage>769</fpage><lpage>779</lpage><pub-id pub-id-type="pmid">25452552</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1128/IAI.02345-14</pub-id><pub-id pub-id-type="pmcid">PMC4294243</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation id="sref39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sambuy</surname><given-names>Y.</given-names></name><name name-style="western"><surname>De Angelis</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ranaldi</surname><given-names>G.</given-names></name><etal/></person-group><article-title>The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics</article-title><source>Cell Biol Toxicol</source><volume>21</volume><year>2005</year><fpage>1</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">15868485</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s10565-005-0085-6</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation id="sref40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trebicka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Macnaughtan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schnabl</surname><given-names>B.</given-names></name><etal/></person-group><article-title>The microbiota in cirrhosis and its role in hepatic decompensation</article-title><source>J Hepatol</source><volume>75 Suppl 1</volume><issue>Suppl 1</issue><year>2021</year><fpage>S67</fpage><lpage>S81</lpage><pub-id pub-id-type="pmid">34039493</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhep.2020.11.013</pub-id><pub-id pub-id-type="pmcid">PMC8973011</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation id="sref41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Camilleri</surname><given-names>M.</given-names></name></person-group><article-title>Leaky gut: mechanisms, measurement and clinical implications in humans</article-title><source>Gut</source><volume>68</volume><year>2019</year><fpage>1516</fpage><lpage>1526</lpage><pub-id pub-id-type="pmid">31076401</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1136/gutjnl-2019-318427</pub-id><pub-id pub-id-type="pmcid">PMC6790068</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation id="sref42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magaña-Montiel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Muriel-Millán</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Pardo-López</surname><given-names>L.</given-names></name></person-group><article-title>XTT assay for detection of bacterial metabolic activity in water-based polyester polyurethane</article-title><source>PLoS One</source><volume>19</volume><year>2024</year><object-id pub-id-type="publisher-id">e0303210</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1371/journal.pone.0303210</pub-id><pub-id pub-id-type="pmcid">PMC11156301</pub-id><pub-id pub-id-type="pmid">38843174</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation id="sref43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jalan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Saliba</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pavesi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure</article-title><source>J Hepatol</source><volume>61</volume><year>2014</year><fpage>1038</fpage><lpage>1047</lpage><pub-id pub-id-type="pmid">24950482</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhep.2014.06.012</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation id="sref44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamath</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Wiesner</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Malinchoc</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A model to predict survival in patients with end-stage liver disease</article-title><source>Hepatology</source><volume>33</volume><year>2001</year><fpage>464</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">11172350</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1053/jhep.2001.22172</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation id="sref45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishijima</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stankevic</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aasmets</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Fecal microbial load is a major determinant of gut microbiome variation and a confounder for disease associations</article-title><source>Cell</source><volume>188</volume><year>2025</year><fpage>222</fpage><lpage>236.e15</lpage><pub-id pub-id-type="pmid">39541968</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.cell.2024.10.022</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation id="sref46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sumner</surname><given-names>L.W.</given-names></name><name name-style="western"><surname>Amberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Proposed minimum reporting standards for chemical analysis: Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI)</article-title><source>Metabolomics</source><volume>3</volume><year>2007</year><fpage>211</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">24039616</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s11306-007-0082-2</pub-id><pub-id pub-id-type="pmcid">PMC3772505</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation id="sref47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giacomoni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Le Corguillé</surname><given-names>G.</given-names></name><name name-style="western"><surname>Monsoor</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Workflow4Metabolomics: a collaborative research infrastructure for computational metabolomics</article-title><source>Bioinformatics</source><volume>31</volume><year>2015</year><fpage>1493</fpage><lpage>1495</lpage><pub-id pub-id-type="pmid">25527831</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1093/bioinformatics/btu813</pub-id><pub-id pub-id-type="pmcid">PMC4410648</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation id="sref48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boudah</surname><given-names>S.</given-names></name><name name-style="western"><surname>Olivier</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Aros-Calt</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Annotation of the human serum metabolome by coupling three liquid chromatography methods to high-resolution mass spectrometry</article-title><source>J Chromatogr B Analyt Technol Biomed Life Sci</source><volume>966</volume><year>2014</year><fpage>34</fpage><lpage>47</lpage><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jchromb.2014.04.025</pub-id><pub-id pub-id-type="pmid">24815365</pub-id></element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgments</title><p id="p0235">The graphical abstract was partially created in BioRender (<ext-link ext-link-type="uri" id="intref0010" xlink:href="https://biorender.com/ctcm0pc" xmlns:xlink="http://www.w3.org/1999/xlink">https://BioRender.com/ctcm0pc</ext-link>). <xref ref-type="fig" rid="fig7">Figure 7</xref> was created in BioRender (<ext-link ext-link-type="uri" id="intref0015" xlink:href="https://biorender.com/pk055v4" xmlns:xlink="http://www.w3.org/1999/xlink">https://BioRender.com/pk055v4</ext-link>).</p><sec id="sec4"><title>CRediT Authorship Contributions</title><p id="p0240">Camilla Cadoli (Conceptualization: Equal; Data curation: Lead; Formal analysis: Equal; Investigation: Lead; Methodology: Lead; Resources: Equal; Visualization: Equal; Writing – original draft: Lead; Writing – review &amp; editing: Lead)</p><p id="p0245">Sania Arif (Formal analysis: Supporting; Software: Lead)</p><p id="p0250">Wibke Ballhorn (Investigation: Supporting; Methodology: Supporting)</p><p id="p0255">Angela Brieger (Resources: Equal)</p><p id="p0260">Maximilian Joseph Brol (Resources: Supporting)</p><p id="p0265">Florence Castelli (Formal analysis: Supporting; Methodology: Supporting; Software: Supporting)</p><p id="p0270">Hans-Peter Erasmus (Resources: Supporting)</p><p id="p0275">Julia Fischer (Data curation: Supporting; Resources: Supporting)</p><p id="p0280">Robert Gurke (Data curation: Supporting; Formal analysis: Supporting; Methodology: Supporting; Software: Supporting)</p><p id="p0285">Lisa Hahnefeld (Data curation: Equal; Formal analysis: Equal; Methodology: Equal; Software: Equal)</p><p id="p0290">Christophe Junot (Formal analysis: Supporting; Methodology: Supporting; Resources: Supporting)</p><p id="p0295">Nico Kraus (Data curation: Supporting; Resources: Equal)</p><p id="p0300">Cristina Ortiz (Methodology: Supporting)</p><p id="p0305">Robert Schierwagen (Data curation: Equal; Formal analysis: Equal; Resources: Equal)</p><p id="p0310">Sara Garcia Torres (Methodology: Supporting)</p><p id="p0315">Frank Erhard Uschner (Resources: Supporting)</p><p id="p0320">Volker Müller (Data curation: Supporting; Methodology: Supporting; Supervision: Equal)</p><p id="p0325">Jonel Trebicka (Conceptualization: Equal; Data curation: Equal; Funding acquisition: Lead; Resources: Equal)</p><p id="p0330">Christoph Welsch (Conceptualization: Equal; Data curation: Equal; Funding acquisition: Lead; Investigation: Equal; Resources: Equal)</p><p id="p0335">Volkhard A.J. Kempf (Conceptualization: Lead; Funding acquisition: Lead; Project administration: Lead; Resources: Lead; Supervision: Lead; Writing – original draft: Equal; Writing – review &amp; editing: Equal)</p></sec></ack><fn-group><fn id="d36e2505"><p id="ntpara0010"><bold>Conflicts of interest</bold> The authors disclose no conflicts.</p></fn><fn id="d36e2509"><p id="ntpara0015"><bold>Funding</bold> The project has been funded by the <funding-source id="gs1">Hessian Ministry of Science and Art</funding-source> within the LOEWE Excellence Program, State Offensive for the Development of Scientific and Economic Excellence, consortium ACLF-I (Acute-on-Chronic-Liver-Failure Initiative [project P5]). Regarding the metabolomics analysis of human sera, Lisa Hahnefeld and Robert Gurke were supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) project number 445757098 and SFB 1039 Z01. Jonel Trebicka was supported by the German Research Foundation (DFG) project ID 403224013 – SFB 1382 (A09) and by the German Federal Ministry of Education and Research (BMBF) for the DEEP-HCC project. The MICROB-PREDICT (project ID 825694) and DECISION (project ID 847949) projects have received funding from the European Union’s Horizon 2020 research and innovation program. The manuscript reflects only the authors’ views, and the European Commission is not responsible for any use that may be made of the information it contains. The funders had no influence on study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn><fn id="d36e2516"><p id="ntpara0020"><bold>Data Availability</bold> The authors are committed to transparency and will make all relevant data, analytic methods, and laboratory materials available to other researchers upon reasonable request to the corresponding author. Due to ethical constraints, material and data related to patients cannot be shared.</p></fn></fn-group></back></article>